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Diabetes mellitus affects approximately 350 million people worldwide, leading to 
the death of about 4.6 million people per year. As a complication of diabetes, 30-40 
percent of patients age 50 and older develop peripheral artery disease (PAD). The current 
standard of care treatments for PAD includes surgical revascularization with bypass 
grafting or percutaneous interventions. However, these interventions cannot be performed 
in a significant portion of patients, and many do not respond to these therapies. An 
alternative approach for treating PAD is to use proteins to stimulate the body to create 
new vasculature, thus restoring blood flow through its own regenerative processes. Stem 
cell factor (SCF) is a cytokine that acts through the receptor tyrosine kinase c-Kit to 
regulate hematopoiesis and has been a candidate protein for treating PAD. Clinical use of 
soluble SCF would be highly beneficial but has been limited due to toxicity related to 
mast cell activation. SCF also exists in a transmembrane form that has differential 
activity from soluble SCF and has not been explored as a therapeutic agent. To explore 
the transmembrane SCF (tmSCF) as a therapeutic we created formulations of tmSCF 
embedded in proteoliposomes or in lipid nanodiscs. Mouse models of anaphylaxis and 
ischemia revealed the tmSCF-based therapies did not activate mast cells and were 
effective in improving the recovery from ischemia in both wild type and diabetic mice. 
 ix 
We also found that the formulation of the lipid nanocarrier to deliver tmSCF altered the 
biological response and trophism of the tmSCF-based treatments. Proteoliposomal 
tmSCF preferentially acted on mature endothelial cells to induce angiogenesis while 
tmSCF nanodiscs had greater activity in inducing stem cell mobilization from the bone 
marrow and recruitment to ischemic sites. A mechanistic analysis of the effects of the 
treatments on mast cells, mature endothelial cells and endothelial progenitor cells, 
revealed that the nanocarriers altered the relative utilization of clathrin- versus caveolin-
mediated uptake pathways of c-Kit in response to the treatments. Overall, our studies 
support tmSCF-based therapies can provide therapeutic benefits without off-target effects 
on mast cells and that lipid nanocarriers can be used to tailor the properties of membrane 
protein-based therapeutics.  
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causing degradation and anaphylaxis, while they use caveolin/clathrin to 
uptake tmSCF-based treatments (slow uptake), reducing the degradation and 
anaphylaxis. (B) Endothelial cells use both of clathrin and caveolin to uptake 
SCF (fast uptake), triggering tube formation of endothelial cells. Endothelial 
cells use both of clathrin and caveolin to uptake tmSCFPL (medium speed 
uptake), triggering tube formation of endothelial cells and therapeutic 
angiogenesis. (C) EPCs use clathrin to uptake SCF (fast uptake), triggering 
colony formation of EPC. EPCs use caveolin to uptake tmSCF-based 
treatments (slow uptake), leading to colony formation and angiogenesis. 
Treatment with tmSCFND further induced CD34-CD133+EPC peripheral 














Chapter 1: Introduction 
1.1 MOTIVATION 
Diabetes mellitus affects approximately 350 million people worldwide, leading to the 
death of about 4.6 million people per year1,2. As a complication of diabetes, 30 to 40 percent of 
patients age 50 and older develop peripheral artery disease (PAD)3. Severe PAD increases the 
risk of non-healing ulcers, pain from intermittent claudication and limb amputation. There are 
several reports stating that diabetic patients possess altered gene expression, which may be a 
causal factor for severe PAD conditions. An understanding of the changes in gene expression in 
the skin of diabetic patients may provide insight into the processes and mechanisms that precede 
the formation of non-healing ulcers. In the first half of this thesis, I investigated the genome wide 
changes in gene expression in skin between patients with type 2 diabetes and non-diabetic 
patients using next generation sequencing. I compared the gene expression in skin samples taken 
from 27 patients (13 with type 2 diabetes and 14 non-diabetic). This information may be useful 
in identifying the causal factors and potential therapeutic targets for the prevention and treatment 
of diabetic related diseases. 
The current standard of care treatments for PAD includes surgical revascularization with 
bypass grafting or percutaneous interventions such as angioplasty, stenting and atherectomy. 
However, these interventions cannot be performed in a significant portion of patients, and many 
do not respond to these therapies4. An alternative approach for treating ischemic disease is to 
stimulate the body to create new vasculature, thus restoring blood flow through its own 
regenerative processes. Several approaches have been attempted including the delivery of 
progenitor cells5,6, viral vectors to express growth factor/angiogenic transcription factor genes7-10 
or through the delivery of growth factors11-13. While cell therapy is labor-intensive and gene 
therapy has safety issues, protein therapeutics such as growth factor treatments have potential 
advantages from delivery and safety perspectives6. 
One potential therapeutic protein for treating ischemic disease is stem cell factor (SCF), 
which signals through the c-Kit receptor (CD117)14. One endogenous SCF isoform (SCF248) is 
initially a transmembrane protein that contains an enzyme cleavable domain allowing its release 
as soluble SCF (SCF163)15. In addition to its well-known role in hematopoiesis, SCF also 
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induces angiogenesis, enhances recovery from stroke and improves recovery after myocardial 
infarction16-18. In many studies, SCF has a synergetic effect with granulocyte colony-stimulating 
factor (G-CSF) to enhance angiogenesis and neurogenesis after stroke in animal studies17,19,20. 
Several clinical trials demonstrated increased peripheral blood progenitor cell mobilization after 
co-stimulation with SCF and G-CSF (Filgrastim)21,22. While SCF has therapeutic potential, 
clinical studies found that patients injected with SCF had mast cell degranulation leading to the 
formation of a wheal and flare response23. The examination of these injection site reactions by 
transmission electron microscopy demonstrated extensive degranulation of dermal mast cells23. 
Moreover, Johnsen et al. reported in a phase II clinical study that 13% of the patients who 
received the combination therapy of SCF and G-CSF suffered from intense allergic episodes, 
including in some cases fever and rigor. Furthermore, 3% of the patients experienced hepatic 
failure24. Based on these and other findings, researchers concluded that a phase III trial of 
treatments using soluble SCF were inadvisable 24. 
The shorter isoform of SCF (SCF220), lacking a cleavable domain at exon 6, is known as 
a tmSCF. Transmembrane SCF is found in the stromal cells of the bone marrow where it 
functions to support the proliferation and survival of progenitor cells25. Soluble and 
transmembrane SCF differ in terms of their ability to activate the c-Kit receptor, induce cellular 
responses and ability to promote adhesion between hematopoietic stem cells and extracellular 
matrix14,26. Several reports have further demonstrated that tmSCF caused more prolonged 
activation of the c-Kit receptor27 and induced longer term proliferation of CD34+ hematopoietic 
cells in comparison to soluble SCF28. Most importantly, it is possible that tmSCF may not cause 
mast cell activation.  
In the second half of this study, I developed therapeutics based on tmSCF embedded in 
lipid nanocarriers. I found that tmSCF-based therapies do not induce mast cell activation in mice, 
in contrast to soluble SCF. Trafficking studies demonstrated that mast cells mainly use clathrin-
mediated endocytosis to uptake SCF, while they use both clathrin- and caveolin-mediated 
endocytosis to uptake tmSCF therapies. I further found that tmSCF nanodiscs and 
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proteoliposomes enhanced the recovery of wild type and ob/ob mice following the induction of 
hind limb ischemia. Mechanistic studies suggest that proteoliposomal formulation enhances 
angiogenic activity of endothelial cells while nanodisc formulation enhances the mobilization of 
endothelial progenitor cells, thus contributing to the recovery from ischemia. Overall, our 
tmSCF-based protein therapies suggest safe potential therapeutics for PAD to diabetic patients 
who have reduced response to growth factor therapy. 
 
1.2 DISSERTATION ROADMAP 
 The motivation behind this dissertation and the comprehensive summary of the thesis 
research are introduced in Chapter 1. A brief background and prior work are discussed in 
Chapter 2. Chapter 3 describes the gene expression changes in skin from patients with type 2 
diabetes to identify the causal factors and potential therapeutic targets for the prevention and 
treatment of diabetic related disease. The development of tmSCF-based therapies and their 
functional examination are described in chapter 4, where I conducted Evan’s blue dye 
extravasation, hind limb ischemia studies on WT type and ob/ob mice, and EPC mobilization 
study. Chapter 5 describes the mechanistic studies on SCF and tmSCF-based therapies to 
decipher endocytosis mechanisms behind the SCF and tmSCF-based therapy. Protein uptake 
kinetics, signaling, and endocytosis studies on three different cell types including mast cell, 
EPCs, and endothelial cells were conducted. Chapter 6 concludes the dissertation and presents 









Chapter 2: Background 
2.1 TYPE 2 DIABETES AND NON-HEALING ULCERS 
Diabetes mellitus affects approximately 350 million people, leading to the death of about 
4.6 million people in the world2,29. Diabetic patients have abnormal pancreatic function which 
leads to glucose insensitivity and deficiency of insulin hormone. A host of other problems 
accompany diabetes including to heart disease, stroke, hypertension, hypercholesterolemia, 
neuropathy, nephropathy, chronic kidney disease, peripheral vascular disease, non-alcoholic fatty 
liver, periodontal disease, erectile dysfunction, loss of hearing, depression, and pregnancy 
complications30.  
Diabetes leads to a disturbance of the blood vessel wall through promotion of vascular 
inflammation and endothelial cell dysfunction31,32. These abnormalities increase the severity of 
vascular disease in diabetic patients33. A major complication of diabetes is the formation of non-
healing ulcers. Patients with type 2 diabetes are prone to the development of non-healing ulcers, 
particularly on the lower limbs34. These non-healing ulcers are a major factor in the cost of 
treating diabetes. It is estimated that non-healing ulcers add 9-13 billion dollars to the overall 
annual cost of treating diabetes in the United States alone35. A wide variety of treatments have 
been explored to heal or prevent these ulcers from forming36. However, the majority of these 
treatments have been found to either be ineffective in clinical trials or have limited benefits in a 
subset of patients37.  
2.2 PERIPHERAL ARTERY DISEASE AND ITS CURRENT STANDARD CARE 
As a complication of diabetes, 30 to 40 percent of patients age 50 and older develop 
peripheral artery disease (PAD)3. Severe PAD increases the risk of non-healing ulcers, pain from 
intermittent claudication and worst case for limb amputation. Current standard cares of PAD 
include physical therapy, medication, and surgical revascularization. The goals of PAD therapy 
depend on the severity of the disease. For all patients with PAD, reducing the risk of 
cardiovascular morbidity and mortality is the primary concern. For patients with intermittent 
claudication, improving functional status is an additional goal. Finally, for patients with critical 
limb ischemia, preventing leg amputation, restoring mobility, and reducing mortality are of 
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paramount concern. Depending on the population and the goal, different treatment choices 
should be discussed.  
 
Exercise  
Patients with intermittent claudication have been treated for their leg symptoms with 
medical therapy, lifestyle modification, and exercise programs because of the low overall risk of 
limb-threatening ischemia. In patients with claudication, a supervised exercise program is 
recommended to improve functional status and quality of life and to reduce leg symptoms. 
Exercise will increase the nitric oxide synthase activity and prostacyclin to improve endothelial 
function. Exercise also reduces free radicals, helping to reduce inflammation. Exercise also 
upregulates VEGF, leading to a possible angiogenesis38.  
 
Medication 
Cilostazol has been shown to significantly improve maximal walking distance39 and is, 
therefore, considered a Class I therapy in the ACC/AHA practice guidelines40. Cilostazol 
increases blood flow to the limbs both by preventing blood clots and by widening the blood 
vessels. Common side effects of this medication include headache and diarrhea. An alternative 
medication to cilostazol is pentoxifylline, which rarely has side effects though occasionally 
patients complain of nausea and diarrhea. However, a previous study comparing cilostazol, 
pentoxifylline, and placebo found cilostazol to be superior by improving maximal walking 
distance by 24 weeks while pentoxifylline was not different from placebo39. 
 
Surgery41 
Once patients develop severe symptoms, surgical intervention should be considered. 
Multiple strategies for revascularization include surgery, angioplasty (cryoplasty, drug-coated, 
cutting, and standard angioplasty balloons are available for use in peripheral arteries), stenting 
(self-expanding and balloon-expandable stents are available, but drug-eluting stents are not 
currently approved for treating peripheral arteries in the United States), and atherectomy (laser, 
directional, orbital, and rotational atherectomy devices are approved for use in the United States).  
During my hospital visit thanks to the courtesy of Dr. Terreson, I had a chance to observe an 
atherectomy surgery on a PVD patient. A surgeon used a magnetic navigation system (MNS) to 
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enable the precise control of catheter42 (Figure 2.1). The tip of the catheter for MNS is softer 
than conventional catheter tips. Moreover, a surgeon can control the catheter head very precisely 
(can move by 1mm and 1̊). Thanks to these technological advancements, more hospitals started 
to use MNS, and a growing number of PVD cases were treated by MNS. 
2.3 NON-INVASIVE THERAPY FOR PERIPHERAL VASCULAR DISEASE 
Though angioplasty, stenting or grafting are the current standard care for PAD, these 
revascularization methods are invasive to blood vessels, sometimes causing re-occlusion of 
blood vessels called restenosis. An alternative approach for treating ischemic disease is to 
stimulate the body to create new vasculatures to restore blood flow through its own regenerative 
processes. Several approaches have been tried, which includes the delivery of progenitor cells5,6, 
viral vectors to express growth factor/angiogenic transcription factor genes7-10 or through the 
delivery of growth factors11-13. While cell therapy is labor-intensive and gene therapy has safety 
issues, protein therapeutics such as growth factor treatments have potential advantages from 
delivery and safety perspectives6. 
2.4 ANGIOGENESIS, VASCULOGENESIS, AND ARTERIOGENESIS 
The term, vasculogenesis, is usually used in developmental biology, describing new 
vascular formation in embryo or fetal body by vascular progenitor cells. In this section, 
vasculogenesis is used to describe new vascular formation in adults by endothelial progenitor 
cells. When an organ or a tissue becomes ischemia, our body tries to create new vasculature to 
supply oxygen and nutrients to the ischemic area. There are mainly three ways to create 
vasculature: angiogenesis, vasculogenesis, and arteriogenesis.  
In angiogenesis, the key player to build blood vessels is the endothelial cell. Hypoxic 
condition at ischemia promotes cells to activate HIF-1 expression and release pro-angiogenic 
factors including VEGF, EGF, FGF, or TGFβ. Hypoxia also upregulates protease expression 
such as MMP, leading to the basement membrane degradation and pericyte detachment43. 
Activated endothelial cells by these growth factors migrate towards ischemic areas to build new 
blood vessels by sprouting from existing blood vessels.  
In vasculogenesis, the key player to build blood vessels is endothelial progenitor cells 
(EPCs). EPCs are usually found in bone marrow, circulating blood, and umbilical cord. After 
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ischemic events, circulating EPCs are mobilized and recruited to ischemic sites and contribute to 
vessel growth or repair.  
Arteriogenesis describes the growth of functional collateral arteries from preexisting 
arterio-arteriolar anastomose, usually seen as a maturation and a formation of larger-diameter 
arteries from preexisting capillaries or collateral arteries. While angiogenesis is induced by 
hypoxia and results in new capillaries, arteriogenesis is induced by physical forces, most 
importantly fluid shear stress. Altered fluid stress induces a vascular wall cell proliferation and 
migration and leads to wall remodeling processes44. 
 Our therapeutic angiogenesis using tmSCF protein aims to trigger both angiogenesis and 
vasculogenesis.  
2.5 STEM CELL FACTOR AND TRANSMEMBRANE STEM CELL FACTOR 
Stem cell factor (SCF) is known as Kit ligand, mast cell growth factor, or steel factor. 
SCF is a hematopoietic cytokine that triggers its biological effects by binding to its receptor, c-
Kit, and maintains hematopoiesis14. Endogenous SCF isoform (SCF248) is initially a 
transmembrane protein that contains an enzyme cleavable domain allowing the release of soluble 
SCF (SCF163)15. While the main role of SCF is to maintain hematopoiesis, further studies 
demonstrated that SCF has a potential to induce angiogenesis and help repair ischemic areas in 
vitro and in vivo16-18. For example, Matsui et al. demonstrated an improved migration and tube 
formation of endothelial cells after SCF treatment in vitro16, and Yaniz-Galende et al. 
demonstrated that SCF gene transfer promoted a cardiac repair after myocardial infarction in 
vivo18. In addition to these studies, SCF is most known for its synergetic effect with granulocyte 
colony stimulating factor (G-CSF) in terms of rescuing ischemia. Co-stimulation of SCF and G-
CSF enhanced angiogenesis and neurogenesis on stroke models both in animal and clinical 
studies17,19,20. These clinical trials demonstrated a higher number of peripheral blood progenitor 
cell mobilization after co-stimulation of SCF and G-CSF in comparison to control45. Though 
SCF was a potential protein for ischemia treatment, various clinical studies demonstrated that 
virtually all patients who have been given SCF have a pruritic wheal and flare response at the 
injection23. Examination of these injection site reactions by transmission electron microscopy 
revealed evidence of extensive anaphylactic-type degranulation of dermal mast cells23.  
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SCF also exists in a membrane bound form, the shorter isoform (SCF220) lacking exon 6, 
which encodes the cleavable domain and remains as transmembrane protein, transmembrane 
stem cell factor (tmSCF). Because membrane-bound SCF is produced by and present on bone 
marrow stromal cells, it functions within the marrow microenvironment to support the 
proliferation and survival of progenitor cells25. Soluble and transmembrane SCF differ in terms 
of their abilities to activate the c-Kit receptor, induce cellular responses and promote adhesion 
between hematopoietic stem cells and extracellular matrix14,26. Several reports have further 
demonstrated that tmSCF caused more prolonged activation of the c-Kit receptor27 and induced 
longer term proliferation of CD34+ hematopoietic cells in comparison to soluble SCF28.  
2.6 C-KIT RECEPTOR29 
The c-Kit is a cell surface receptor that binds to SCF, and belongs to receptor tyrosine 
kinase (RTK). When SCF binds to the extracellular domain of c-Kit, its dimerization is triggered 
with other adjacent c-Kit. Dimerization leads to a rapid activation of the protein's cytoplasmic 
kinase domains. The first substrate for being phosphorylated by this kinase domain is the 
receptor itself. The activated receptor as a result then becomes autophosphorylated on multiple 
specific intracellular tyrosine residues, driving downstream signal transduction pathway. 
The c-Kit is usually detected in various stem cells, cells with self-renewal potency, or 
progenitor cells. The c-Kit expressing cell type includes hematopoietic cells, germ cells, mast 
cells, and melanoma cells etc. As stem cells differentiate, they lose c-Kit expression. 
Approximately 1% to 4% of bone marrow stem cells are c-Kit positive and 1% in peripheral 
blood. Other than these locations, c-Kit are also found in epithelial cells, neurons, or endothelial 
cells.  
2.7 PROTEOLIPOSOME 
Liposome is one kind of lipid based nanocarriers often used as a drug delivery carrier. 
Liposome is made of phospholipid bilayers mimicking the cellular membrane. Polar head group 
facing outside, allowing interaction with aqueous solution while having non-polar chains, 
promoting interaction with one another to create a lipid bilayer vesicle. Liposomes are the most 
successful drug carrier because of their unique advantages. They can contain hydrophilic agents 
inside of aqueous core as well as insert lipophilic agents on the membrane. Hydrophilic surface 
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of the liposomes makes them less likely to be bound with serum, leading to less opsonization. 
Lamellarity also contributes to drug delivery efficiency. Unilamellar vesicles enclose a large 
aqueous core, thus they are ideally suited for the encapsulation of hydrophilic drugs. On the 
other hand, multilamellar vesicles preferentially entrap lipid-soluble drugs46.  
In this study, we used four types of lipid to make liposome. 1,2-Dioleoyl-sn-glycero-3-
phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (18:1 (Δ9-Cis) PE 
(DOPE)), Sphingomyelin and Cholesterol. Phosphatidylcholine (PC) is generally the most 
abundant lipid in animal cell membranes, providing structural framework. PC is more common 
in the outer leaflet where it functions as part of the permeability barrier47. DOPE forms a stable 
lipid layer and fuses with endosomal lipid bilayer. DOPE or DOPC are neutral lipids and usually 
studied with 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) for its in vitro transfection 
efficiency48. Sphingomyelin is highly abundant in a membrane of nerve cells (i.e. myelin 
sheaths). Sphingomyelin has a high affinity for cholesterol, they are packed tightly into liquid-
ordered domains to form lipid rafts. These raft domains are thought to function as signaling 
platforms that regulate the localization and interactions of proteins49. Cholesterol consists of four 
linked hydrocarbon rings, forming a bulky steroid structure. Cholesterol is particularly useful in 
proteoliposome creation since it fills the gaps created by imperfect packing of other lipid species 
when proteins are embedded in a membrane. Although cholesterol is often used as liposome 
content, it presents some problems when used in human pharmaceuticals. Since commercially 
available source is from animals (sheep derived), it may cause a potential viral contamination. 
Moreover, cholesterol is readily oxidized and these oxidized products tend to be toxic in the 
biological system (i.e. cholesterol causes aortic smooth muscle cells to die)50. Therefore, care 
must be taken to handle cholesterol not to oxidize it (i.e. store in argon gas). We used 
DOPE:DOPC:Cholesterol:Shingomyelin = 2:1:1:1 ratio, providing liposome flexibility to 
incorporate tmSCF protein.  
2.8 NANODISC 
In 2007, Sligar and coworkers at the University of Illinois at Urbana-Champaign 
developed a new technology termed as nanodiscs51. Nanodiscs are essentially small nanoscale 
lipid bilayers that allow for the solubilization of membrane protein in a uniform, membrane-
mimicking environment. Nanodiscs have several advantages over other types of lipid bilayer-
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mimicking technologies, including their homogeneity, control of membrane protein oligomeric 
state and long-term stability52. Because of these advantages, nanodiscs are usually used for 
studying membrane protein’s properties. In our study, we used nanodisc as a protein carrier to 
improve therapeutic efficiency of membrane protein. Nanodisc is composed of Membrane 
Scaffold Protein (MSP), lipid, and target protein. It is made through self-assembly using 
detergent solubilizing methods. MSP is wrapping the lipid and protein, and forming a nanodisc 
when detergent is removed. The stoichiometric ratio of lipid, MSP, and target protein is 
important to make nanodisc. If this ratio is off, aggregates of lipid, protein and MSP will be 
formed. In our protocol, we removed these free proteins/lipids by dialysis with a membrane (the 
pore size is 300kDa). We use 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) as a 
lipid source, which is typically considered as one of the model lipids for biophysical 
experiments. Unsaturated lipids in POPC provide nanodisc fluidity, allowing membrane proteins 
to be incorporated. The structures of all the lipids used in this study are shown in Figure 2.2. 
2.9 ENDOTHELIAL PROGENITOR CELLS 
 EPCs were first discovered by Asahara et al. in 1997, reporting the bone marrow derived 
circulating progenitor cells for endothelial lineage53. Stem cells have been traditionally 
characterized based on three properties: self-renewability, clonogenicity, and plasticity 
(differentiation capacity). In contrast, progenitor cells lack self-renewability. EPC has self-
renewability and clonogenicity but does not have plasticity (Figure 2.3) thus it is between stem 
cell and progenitor cell 54. In this section, I will describe the origin of EPC, markers for EPC, 
culture method, subtypes of EPCs, and their niche.  
EPCs share a common origin with hematopoietic cells. They originated from 
hemangioblast, which is a transient cell that forms in embryo during gastrulation and has an 
ability to rapidly differentiate into an endothelial or a hematopoietic stem cell54 (Figure 2.3). 
Since EPCs are of hematopoietic origin, EPCs share some common markers with hematopoietic 
cells. Examples include CD34 (transmembrane phosphoglycoprotein protein), CD133 (prominin-
1) and CD45 (Protein tyrosine phosphatase, receptor type, C). CD34 mediates the attachment of 
hematopoietic stem cells to bone marrow extracellular matrix or directly to stromal cells. The 
precise function of CD133 remains unknown, but it has been proposed that it acts as an organizer 
of cell membrane topology. EPCs also share some common markers with endothelial cells such 
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as CD31 (PECAM-1), FLK-1(Fetal Liver Kinese-1), and CD144(VE-cadherin). CD31 is known 
as platelet/endothelial cell adhesion molecule-1 (PECAM-1), which regulates cell adhesion thus 
controlling migration and inflammation of endothelial cell55. FLK-1 is known as VEGFR2 and 
regulates vascular development and angiogenesis. CD144 is VE-cadherin, regulating various 
cellular processes such as cell adhesion, proliferation, apoptosis and vascular endothelial growth 
factor receptor function. Though CD34 is a potential marker for EPC, it is a widely expressed 
molecule on some mesenchymal, epithelial, and even cancer stem cell populations. FLK-1 is also 
widely expressed on blood, endothelial, and cardiac cells and thus fails to be a helpful 
discriminator among those cells expressing CD34. Thus, we need multiple markers to detect 
EPCs. So far, general consensus purports that it would be sufficient to use CD34, CD133, and 
FLK-1 as EPC marker. In our study, we used CD34, CD133, FLK-1 and CD144 to determine 
EPCs.  
Though there is a general consensus for markers for EPC, it is a very controversial topic 
since some studies found these markers on EPCs but some claimed not. These discrepancies 
happen because EPCs have several subtypes and their culture method is modified by various 
researchers.  
The first subtype is early EPC, which can be found after one week of culturing bone 
marrow mononuclear cells (BMMNCs) from blood or bone marrow in endothelial cell media. 
Their morphology is spindle shape. To obtain early EPC, we generally have two methods: 
depletion method or re-plating method. The depletion technique involves plating BMMNCs on 
fibronectin-coated dishes for approximately four days. The nonadherent cells are then removed 
by washing with PBS, leaving BMMNCs on a dish. The four-day period is selected because the 
unwanted platelets, red blood cells, or monocytes are gradually depleted over this period. The 
number of days is, however, not fixed and has been modified by various researchers. In the re-
plating method, we first pre-plate the BMMNCs from bone marrow or blood then re-plate the 
non-adherent cell. The rationale for pre-plating the BMMNCs is to remove any monocytes, 
macrophages, or circulating mature ECs that might be present in the BMMNCs sample54. In 
these culture methods, each researcher uses different kinds of endothelial cell media, different 
days to select EPCs. These inconsistencies may contribute to the variety of marker expressions 
for EPC.  
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The second subtype of EPC is called late EPC, which appears after one to three weeks of 
culturing early EPCs. Their appearance will shift from spindle shape to cobblestone like shape. 
This phenotype is functionally closer to endothelial cells, having enhanced LDL uptake, nitric 
oxide production, and lectin binding in comparison to early EPC. Markers for late EPCs are 
more consistent among articles. Late EPC loses CD133 expression and maintains CD34, FLK-1, 
CD144. Marker expression, morphology, functional activities are summarized in Table 154.  
EPCs are found in peripheral blood, umbilical cord blood and bone marrow. EPCs are 
most abundant in umbilical cord blood but their population is still 0.2-1% of total cord blood56. 
Population of EPC in bone marrow and peripheral blood are even less and reported to be around 
0.002-0.01%57. These resident EPCs will increase in response to physiological and pathological 
stimuli, including myocardial and peripheral ischemia58. 
2.10 CLATHRIN MEDIATED ENDOCYTOSIS59 
Clathrin is composed of a clathrin heavy chain (~190 kDa) and a smaller clathrin light 
chain (~25 kDa). Three clathrin heavy and light chains form a trimeric clathrin ‘triskelion’, 
structuring polygonal lattices (Figure 2.4 A, B). When a cargo molecule is endocytosed, clathrin 
is assembled on the membrane. However, clathrin does not have an affinity to the plasma 
membrane, thus requiring aids of adaptor proteins. Cargo molecules are usually transmembrane 
proteins and their extracellular ligand. In this research, cargo molecules are c-Kit. After a ligand 
binds to c-Kit, c-Kit will recruit cascades of adaptor proteins. These adaptor proteins then recruit 
clathrins, starting to form a clathrin pit and generating vesicles. These processes are relatively 
fast and only take 120 seconds to generate a vesicle (Figure 2.4 C). These vesicles are then 
fused with an early endosome to initiate an intracellular trafficking event. 
2.11 CAVEOLIN MEDIATED ENDOCYTOSIS60-62 
Caveolin-1 is a small integral membrane protein, whose 34 hydrophobic amino acids are 
inserted into the inner leaflet of the membrane bilayer in a special hairpin-like form and never 
reaches the outside of the cell. The rest of the protein is cytosolic and the N-terminal region has 
been suggested to be important for anchoring caveolin to cholesterol and sphingolipid-rich 
membrane domains. Biochemical studies revealed that caveolae are detergent resistant and 
highly hydrophobic, usually surrounded by cholesterol or sphingomyelin, thus believed to be in 
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lipid raft domain. Caveolin serves an important role in lipid metabolism. Caveolin 1 in adipocyte 
binds to fatty-acid and supports the formation of lipid droplets (intracellular organelles 
specialized for lipid storage). Another evidence of linking caveolin and lipid metabolism is that 
Cav1-knockout mice are resistant to diet-induced obesity and show decreased adiposity as well 
as decreased levels of free cholesterol in adipocytes. These studies indicate that caveolae may 














Figure 2.1. Image of magnetic navigation system and catheter head. Physicians control a 
catheter using a robot in the control room. Images taken from Ramcharitar et al. Nature Clinical 















Figure 2.2. Structures of lipids used in this study. 1,2-Dioleoyl-sn-glycero-3-phosphocholine 
(DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (18:1 (Δ9-Cis) PE (DOPE)), 1-

















Figure 2.3. Origin of EPCs. EPCs share the same origin with hematopoietic stem cells, and they 














Figure 2.4. Structure of clathrin and schematic illustration of clathrin-mediated 
endocytosis. (A) 3D model structure of clathrin vesicle. (B) Electron microscopy image of 
clathrin pit. (C) Schematic illustration of clathrin pit formation. Images taken from Kaksonen, M. 












Table 2.1 Summary of activity and surface expression of early EPCs and late EPCs. Table 
















Chapter 3: Altered Gene Expression in the Skin of Type 2 Diabetes 
3.1 INTRODUCTION 
Type 2 diabetes affects 29 million people in the U.S., and 170 million people in the 
world63. This condition can often lead to the disturbance of the blood vessel wall through 
promotion of vascular inflammation and endothelial cell dysfunction31,32. These abnormalities 
increase the severity of vascular disease in diabetic patients33. A major complication of diabetes 
is the formation of non-healing ulcers. Patients with type 2 diabetes are prone to the development 
of non-healing ulcers, particularly on the lower limbs34. These non-healing ulcers are a major 
factor in the cost of treating diabetes. One estimate suggested that non-healing ulcers add 9-13 
billion dollars to the overall annual cost of treating diabetes in the United States alone35. A wide 
variety of treatments have been explored to heal or prevent these ulcers from forming36. 
However, the majority of these treatments have been found to either be ineffective in clinical 
trials or have limited benefits in a subset of patients37.  
Our group has recently identified that patients with diabetes have a reduction in cell 
surface proteoglycans in their skin, including syndecan-4 and glypican-136,64,65. These 
proteoglycans serve as co-receptors for growth factor signaling and their absence would suggest 
that diabetic tissues would be resistant to growth factor therapies for enhancing angiogenesis and 
wound healing. Delivery of syndecan-4 and glypican-1 in a proteoliposomal formulation 
enhanced the effectiveness of growth factor therapies in diabetic animals in models of limb 
ischemia and wound healing36,65. These studies demonstrated that an increased understanding 
into the biology of non-healing ulcers and the changes that occur in skin with type 2 diabetes 
could identify potentially treatable deficits in healing and angiogenesis that may improve their 
treatment.  
In this chapter, we used RNA sequencing (RNAseq) to examine the changes in gene 
expression in the skin between patients with type 2 diabetes and non-diabetic patients. These 
findings provide a window into the changes that occur in diabetic patients that may predispose 
them to the formation of non-healing ulcers and could provide pathways for further investigation 
into the mechanisms of poor healing in diabetic wounds.1 
 
1 Portions of this chapter have been previously published as 66 Takematsu, E. et al. Genome wide analysis of gene 
expression changes in skin from patients with type 2 diabetes. PLoS One 15, e0225267, 
doi:10.1371/journal.pone.0225267 (2020).  
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3.2 MATERIALS AND METHOD  
3.2.1 HUMAN SAMPLES 
Human skin samples were obtained from the Glasgow Caledonian University Skin Research 
Tissue Bank, Glasgow UK. The tissue bank has NHS research ethics approval to supply human 
skin for research (REC REF: 16/ES/0069). All methods were carried out in accordance with 
relevant guidelines and regulations. All experimental protocols were approved by the NHS East 
of Scotland Research Ethics Service. Informed consent was obtained from all subjects (no 
patients were under 18 years of age). All the patients were Caucasian and from western Scotland. 
Patients with diabetes were on treatment with metformin. Samples were formalin fixed and 
embedded in paraffin following standard procedures prior to sectioning. Control skin samples 
were taken from either clinical cases of breast reduction surgery or lower limb interventions for 
peripheral arterial disease. Skin samples for diabetic patients were taken from limb amputation 
surgeries. Metadata for the patients are listed in Table 1.  
3.2.2 RNA SEQUENCING AND ANALYSIS 
RNA was isolated from formalin-fixed, paraffin-embedded tissue sections using the 
RNeasy FFPE kit (Qiagen). The mRNA was sequenced using an Illumina HiSeq 4000 at the 
Genomic Sequencing and Analysis Facility at UT Austin. Single reads of 50 base pairs were 
performed after poly-A mRNA capture used Ambion Poly(A) Tailing Kit and NEBNext Ultra II 
Directional RNA Library Prep Kit to isolate mRNA and dUTP directional preparation of the 
mRNA library. Gene expression analysis was performed using DESeq2 and R software. Plots 
were created using Prism GraphPad and Microsoft Excel.  
3.2.3 STATISTICAL ANALYSIS 
Gene abundances were then normalized using DESeq2 normalization and log2 
transformed using variance-stabilizing transformation (VST). Differential expression testing was 
performed based on the DESeq2 negative binomial distribution by comparing type II diabetic 
samples to normal samples, while controlling for sex differences. This was done by including sex 
as a covariate to control for in the DESeq2 design matrix along with the factor of interest, 
diabetic state. Genes that met the adjusted p-value cutoffs of 0.05 or lower and an absolute fold 
change of 2 or higher. 
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3.3 RESULTS AND DISCUSSION 
3.3.1 OVERALL CHANGES IN GENE EXPRESSION IN THE SKIN IN TYPE 2 DIABETES 
Skin tissues were obtained from 13 non-diabetic and 14 type 2 diabetes donors. We examined 
expression changes of 58,037 transcribed genes. Differential expression testing was performed 
based on the DESeq2 negative binomial distribution by comparing type 2 diabetic samples to 
normal samples. We found 64 significantly upregulated genes and 120 downregulated genes 
(Figure 3.1 A, B). There was significant patient-to-patient variability in the samples (Figure 3.1 
C). Overall the five most upregulated genes when comparing skin samples from diabetic patients 
to non-diabetic patients included three non-coding RNA (lncRNA) genes (LINC01118, RP11-
545I5.3 and an unknown lncRNA), an enzyme involved in lipid metabolism (ABHD16A) and a 
potassium channel that is important in smooth muscle tone and nerve function (KCNMA1). 
Conversely, the most downregulated genes included multiple pseudogenes and lncRNA 
(LINC01060, HPRT1P2, and CCNYL3) as well as the transcription factor NKX2_1 and a 
member of the TPD52 protein family associated with proliferation and vesicle trafficking 
(TPD52L3). Pathway analysis of the significantly altered genes revealed significant alterations in 
genes relating to epigenetic regulation of gene expression, lipid membrane rafts, growth factor 
signaling/PDGFR signaling, and proteolysis (Figure 3.2 A). Gene ontology analysis of the 
biological processes most regulated in the genes and the functional pathways being regulated 
supported significant regulation of genes relating to integrin-based adhesion, focal adhesion 










Figure 3.1 Volcano plots and heat map of z-score. (A) Volcano plot of statistical significance 
against fold change between diabetic and non-diabetic skin. (B) Zoomed volcano plot of 
statistical significance against fold change between diabetic and non-diabetic skin. (C) Heat map 













Figure 3.2 Gene and pathway ontology analysis of significantly regulated genes between 
diabetic and non-diabetic patient skin samples. (A) Most altered pathways between diabetic 
and non-diabetic skin using the reactome database analysis. (B) Significantly alter pathways for 
the gene ontology analysis for biological processes when comparing diabetic and non-diabetic 
patients. (C) Pathways significantly altered using the wikipathways analysis tool comparing 









































3.3.2 REGULATION OF GENES RELATED TO TRANSCRIPTION AND GENE REGULATION  
The largest category of genes with significant regulation was that involved in gene 
regulation (Figure 3.3). Among the 11 upregulated genes, five genes (CAMK4, ZNF106, 
RC3H2, DMNT1, ZNF148) showed some relationship with type 2 diabetes in the previous 
studies67-71. One of the significantly upregulated genes was for calcium/calmodulin-dependent 
protein kinase (CAMK4). This protein phosphorylates transcription factors and can thereby 
regulate gene expression. Its target transcription factors include high-mobility group protein 1 
(HMGB1), a proinflammatory mediator of chronic pain development72. Increased 
phosphorylation of CAMK4 is seen in a rat dorsal root ganglion after STZ-induced diabetes. 73.  
 Another notable gene that was upregulated in patients with diabetes was the 
transcriptional repressor ZNF224. Overexpression of ZNF224 is linked to the reduction of 
mitochondrial citrate carrier (CIC)74,75, a key enzyme in fatty acid and cholesterol synthesis75. 
Rats with STZ-induced diabetes had a reduced CIC activity76, consistent with our findings.    
Among the downregulated genes in our study, seven of these genes were found to also be 
associated with diabetes in previous studies77-84. The most downregulated gene in the gene 
regulation category was NKX2-1, also known as thyroid transcription factor 1 (TTF1). This 
transcription factor is involved in differentiation of the thyroid, lung and brain85 and is linked to 
neuronal disorders86,87. Mutation of NKX2-1 is also related to the reduction in mitochondrial 
respiratory chain complex activity88. Notably, reduced mitochondrial activity is one of the 
characteristics of diabetes89. Another highly downregulated transcription factor was SIX4, a key 
transcription factor in the development of sensory neurons and myogenesis90-92. Peripheral 
neuropathy is a common finding in diabetic patients and underlies alterations in biomechanics 
that leads to increased risk of ulcer formation93. In addition, diabetes can cause muscle weakness 
by altering muscle progenitor cells and other mechanisms94,95. Thus, further investigation of 
these genes in the context of reduced mitochondrial activity and deficits in neural and muscular 



























Figure 3.3 Transcription- and regulation-related genes that were significantly regulated in 










3.3.3 REGULATION OF METABOLISM AND MITOCHONDRIAL RELATED GENES.  
We observed significant regulation in a number of genes relating to metabolism (Figure 
3.4 A). The most upregulated gene in this category was α/β hydrolase domain containing 16A 
(ABHD16A), which is a member of the α/β hydrolase domain-containing (ABHD) protein 
family and is expressed in dendritic cells, macrophages, lymphocytes, and lymphoid organs. 
Interplay between ABHD16A and ABHD12 dynamically regulates immunomodulatory 
lysophosphatidylserines and can alter the release of proinflammatory cytokines from 
macrophages96. Other studies found several associations between ABHD16A and the genetic 
predisposition to coronary artery aneurysm and Kawasaki disease97. 
We also found an 11.8 fold increase in gene expression for LDL Receptor Related 
Protein 1 (LRP1) in skin from diabetic patients in comparison to control patients. LRP1 interacts 
with many ligands including lipoproteins, extracellular matrix proteins, protease, cytokines and 
growth factors. Biological roles of LRP1 covers broad ranges of activities such as lipid 
metabolism, cell growth, migration and tissue invasion, but the most notable role of LRP1 in 
terms of wound healing should be extracellular matrix (ECM) remodeling. A recent study found 
that LRP1 markedly inhibited fibronectin remodeling by regulating cell-surface urokinase 
receptors and plasminogen activation98. This process may be relevant to reduced healing of 
wounds and altered ECM remodeling observed in diabetic patients. Another study found 
upregulation of LRP1 in the epicardial fat tissue from patients with type 2 diabetes99. 
Interestingly, GULP1, a ligand that binds to LRP1, was significantly decreased in patients with 
type 2 diabetes in our study. GULP1 is an adapter protein necessary for the engulfment of 
apoptotic cells by phagocytes100 and also functions as a modulator of glycosphingolipid and 
cholesterol transport101.   
We also found an 8.7 fold increase in NOTCH3 expression in skin from patients with 
type 2 diabetes. The Notch3 protein plays a key role in the function and survival of vascular 
smooth muscle cells, and is essential for the maintenance of blood vessels102. Recently, several 
studies found that NOTCH3 polymorphism seems to be a risk factor for both ischemic disease 
and diabetes. For example, NOTCH3 381C>T and 1735T>C polymorphisms found in the 
peripheral blood were associated with ischemic stroke and to be the risk factors for ischemic 
stroke103. The C381T (rs3815188) variants in exon 3 and A684G (rs1043994) variants in exon 4 
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of the NOTCH3 gene in the peripheral blood were also strongly associated with type 2 
diabetes104.  
Superoxide dismutase 2 (SOD2) was increased 4.6-fold in patients with type 2 diabetes in 
our study. This gene encodes a mitochondrial protein, also known as manganese superoxide 
dismutase (MnSOD), that is a manganese-dependent enzyme that acts on superoxide produced as 
a byproduct of oxidative phosphorylation. SOD2 converts superoxide into hydrogen peroxide, 
which can be further detoxified by other enzymes. This enzyme is induced by oxidative stress 
and is increased in chronic ischemic wound models105,106. In addition to its role in protecting 
oxidative damage, SOD2 also regulates signaling through reactive oxygen species (ROS)107. 
Low levels of SOD2 impair wound healing and enhancing SOD2 expression/activity enhanced 
wound repair108,109. Polymorphisms in the SOD2 gene are associated with type 2 diabetes in the 
Japanese American population. The A16V polymorphism of SOD2 was seen frequently in the 
peripheral blood of type 2 diabetes patients, and study confirmed that this polymorphism 
decreases SOD2 activity, which successively will increase oxidative stress110. The C47T 
polymorphism in SOD2 gene has also been associated with a protective effect against diabetic 
microvascular complications111.  
The most downregulated gene in the metabolism category was tumor protein D52-like 
family of proteins (TPD52L3; Figure 3.4 A). This gene has not been linked to type 2 diabetes or 
wound healing yet, but a study found that exogenous expression of human TPD52 in cultured 
cells resulted in significantly increased numbers of lipid droplet.112 Lipid droplets store excess 
fatty acids within adipocytes. Thus, TPD52L3 seems to be associated with excess lipid storage in 
adipose cells. We hypothesize that lowering of TPD52L3 in type 2 diabetes, may lead to 
alterations in lipid storage and altered function of adipocytes.  
Previous studies have linked diabetes to the development of mitochondrial 
dysfunction113. For example, point mutations resulting in amino acid substitutions in MT-CYB 
(D214N) showed defective mitochondrial ATP production114-116. Therefore, it is imperative to 
examine how diabetes affects the expression of mitochondrial related genes. The only 
significantly upregulated mitochondrial gene was HEBP2, which codes for the Heme Binding 
Protein 2 (Figure 3.4 B). The protein encoded by this gene plays a role in the loss of 
mitochondrial membrane potential prior to cell death in necrosis. Methylation on this gene has 
been found in diabetic patients117,118. The most strongly downregulated mitochondrial gene was 
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MFN1, which codes for the mitofusin-1 protein. This protein is expressed on the mitochondrial 
membrane and is involved in the regulation of mitochondrial fusion. A study showed that type 2 
diabetes was related to mitochondrial network fragmentation in myocardium and a large decrease 
in MFN1 expression119. Interestingly, mice with MFN1 knockout displayed a higher preference 
for lipid use as energy substrate120. Among five downregulated genes, three genes were 



























Figure 3.4 Metabolism genes and mitochondrial genes are significantly upregulated or 
downregulated in patients with diabetes. (A) Alterations in metabolism-related genes when 
comparing patients with T2D and non-diabetic patients. (B) Mitochondrial genes that were 










3.3.4 ALTERATIONS IN PSEUDOGENE, LNCRNA, RNA GENE, RNA PROCESSING GENES  
Pseudogene is a DNA sequence that is an imperfect copy of a functional gene. 
Pseudogenes were once thought to be junk DNA, but it has since been recognized that some 
pseudogenes play essential roles in gene regulation of their parent genes122. We found two genes 
upregulated and nine genes downregulated in the pseudogene category (Figure 3.5 A). Putative 
Cyclin-Y-Like Protein 3 is a pseudogene for cyclin-dependent protein serine/threonine kinase. 
The function of CCNYL3 is not yet fully understood, but overall it is expected to relate to the 
regulation of cell proliferation. Double Homeobox 4 Like 9 (DUX4L9), also known as DUX4c, 
is a pseudogene that has similarity to DUX4 transcription factor that was suggested to be a risk 
gene to cause facioscapulohumeral muscular dystrophy123. This gene rapidly downregulates the 
transcription factor Myogenic Differentiation 1 (MyoD), resulting in impaired myogenic 
differentiation and muscle regeneration124. Low expression of DUX4 impairs myogenesis 
through a reduction in myogenic gene expression125. DUX4L9 expression impairs 
myofibrillogenesis and potentially has a role in controlling muscle cell differentiation through 
association with type III intermediate filament protein desmin126,127. 
Recent studies showed that deregulation of lncRNAs is associated with various diseases 
such as cancer, Alzheimer’s disease, and heart disease128-132. We found five upregulated genes 
and six downregulated genes under the long non-coding RNA (lncRNA) category (Figure 3.5 
B). Within the lncRNA category, CPS1-IT1 seems to be involved in type 2 diabetes. In the 
previous study, an impairment in neovascularization results from a high glucose induced defect 
in transactivation of hypoxia-inducible factor-1α (HIF-1α), and HIF-1α is controlled by CPS-
IT1133,134. The lncRNA LINC01118 was the most upregulated lncRNA in patients with type 2 
diabetes in our study. LINC01118 has been associated with chemoresistance and increased cell 
migration in cancer135. The lncRNA LINC01060 was strongly decreased in our study in patients 
with type 2 diabetes. This lncRNA has been associated with poor prognosis in pancreatic cancer 
and inhibited pancreatic cancer proliferation and invasion136. Thus could also potentially 
contribute to poor wound healing prognosis. 
 In the RNA gene category, we found eight downregulated genes (Figure 3.5 C). One of 
the downregulated RNA genes was Calcium-Activated Neutral Proteinase 10 Antisense 1 
(CAPN10-AS1). In a previous study, CAPN10 expression was elevated in a pancreatic islet from 
type 2 diabetes137.  It is generally known that antisense interferes the transcription of paired RNA 
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(sense RNA)138. We also found the RNA gene ERICH3-AS1 to be highly downregulated in 
patients with type 2 diabetes. Consistent with our findings, this gene is downregulated in a sciatic 
nerve in diabetic mice139. Little is known about the function of ERICH3, however it is highly 
expressed in airway cilia and has been associated with major depressive disorder140,141.  
In the RNA processing category (Figure 3.5 D), we found a downregulation of Zinc 
Finger Protein 1 (ZPR1). The ZPR1 binds to the promoter of peroxisome proliferator-activated 
receptor gamma (PPARG) proteins 1 and 2, which play a key role in insulin sensitivity and 
obesity142,143. A previous study reported the evidence linking the genetic susceptibility of 
common variants in ZPR1 to type 2 diabetes with the levels of fasting plasma glucose and blood 
hemoglobin A1c, suggesting ZPR1 might be involved in abnormal glucose metabolism144. 
However, the expression tendency seems to be different in skin tissue and others. ZPR1 mRNA 
in the brain is upregulated in mice fed a high-fat diet145, whereas our result showed 
downregulation in the skin.  
Several other notable genes were regulated in the RNA processing category including 
cysteinyl-tRNA synthetase 2 (CARS2), Heterogeneous Nuclear Ribonucleoprotein R 
(HNRNPR), and DEAH-box helicase 37 (DHX37). CARS2 plays a critical role in protein 
biosynthesis by charging tRNAs with their cognate amino acids. In a previous study, CARS2 
was upregulated in a muscle tissue of patients with type 2 diabetes146. Heterogeneous Nuclear 
Ribonucleoproteins are RNA binding proteins and associated with pre-mRNAs in the nucleus. 
HNRNPR appears to influence pre-mRNA processing and other aspects of mRNA metabolism 
and transport. HNRNPR was downregulated in the islet-specific CD4 + T cells in type 1 diabetes 
-susceptible NOD mice147. DHX37 encodes a DEAD box protein. DEAD box proteins are 
characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD), and implicated in alteration of 
RNA secondary structure such as translation initiation, nuclear and mitochondrial splicing, and 
ribosome and spliceosome assembly. In the previous study, DHX37 was downregulated in rat 
corneal epithelia in type 1 diabetes83,148. Our result also showed a significant downregulation of 
DHX37, implying the malfunction in constructing RNA secondary structures may occur in the 







Figure 3.5 Pseudogene, lncRNA, RNA gene, and RNA processing genes are significantly 
upregulated or downregulated in patients with diabetes. (A) Pseudogenes that were altered 
inin skin from patients with type 2 diabetes. (B) Long non-coding RNAs (lncRNAs) that were 
altered in the skin of patients with type 2 diabetes (C) RNA genes with significant regulation in 
comparing the two patient groups. (D) Genes involved in RNA processing that were significantly 








3.3.5 CYTOSKELETON, MEMBRANE, AND ADHESION RELATED GENES 
Elevated glucose levels can alter the mRNA and protein expression of contractile smooth 
muscle markers149. Figure 3.6 A shows significantly up and downregulated cytoskeleton related 
genes in type 2 diabetic skin. We found -actin (ACTB) to be significantly upregulated in the 
skin of type 2 diabetic patients. We also found increases in the Myosin-IF (MYO1F) gene. 
MYO1F exacerbates atherogenesis and is reported to be a biomarker candidate for patients with 
obstructive coronary artery disease or advanced atherosclerosis150. Among downregulated genes, 
Tropomyosin (TPM3) was downregulated ten-fold in the type 2 diabetic test group. This gene is 
translated into α-tropomyosin, which controls contraction in type I skeletal muscle fibers. 
Consistent with our findings, a previous study showed the downregulation of TPM3 in rats with 
alloxan-induced diabetes151.  
We found 12 genes in this category that were significantly altered in the skin of diabetic 
patients in comparison to control patients (Figure 3.6 B). Cell membrane lipid composition can 
alter the effectiveness of glucose transporters and has been implicated in the microvascular 
pathophysiology in diabetes152. The most upregulated gene in our study was the huntingtin 
interacting protein 1 related protein (HIP1R). This protein serves an important role in clathrin 
mediated endocytosis153. A recent study revealed its function in β-cell survival and glucose-
stimulated insulin secretion, and HIP1R is downregulated in type 1 diabetes154. On the other 
hand, HIP1R expression is increased in the pancreas in type 2 diabetes155. 
 We found a significant decrease in plasmolipin (PLLP) in the skin of patients with type 2 
diabetes. A recent study showed that Notch signaling is mediated by PLLP and STX7 in 
epithelial cells: silencing STX7 impairs activation of Notch through PLLP156,157. In our study, 
both of STX7 and PLLP were significantly downregulated in diabetic patient skin. The Notch1 
pathway is a key regulator of wound healing158. Thus, defects in this pathway may be potential 
targets for improving healing in diabetes.   
Tissue repair or wound healing process requires the regulation of cell adhesion molecules 
to control proliferation or migration of cells. The most upregulated gene in this category was 
RPSA, which codes for the Laminin Receptor 1 (Figure 3.6 C). This gene is differentially 
expressed in wound margins at different sites on the body and has a role in adhesion and 
migration in the intestinal epithelia159,160. We also observed increases in the genes for integrin 3 
and 9, as well as a decrease in gene expression for integrin v. Integrin 31 is suppressed by 
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91 during the resolution wound angiogenesis161. In one study, integrin 31 also inhibited re-
epithelialization in wound healing162. Another study demonstrated that ITGA3 knockout mice 
had inhibited wound healing and that integrin 31 served as an inhibitor of Smad7 during the 
wound healing process163. Integrin v is overexpressed in endothelial cells during the formation 
of new blood vessels and is a key adhesion receptor in many steps of angiogenesis164. In 
addition, v integrins have a role in wound healing through the regulation of TGF- and 
regulation of cell migration165. We also found an increase in von Willebrand factor (vWF) gene 
expression in patients with type 2 diabetes. The protein is involved in platelet adhesion and has a 
role in vascular inflammation and thrombosis166. There have been previous studies showing that 
high levels of VWF are associated with type 2 diabetes167-169. Our study adds to these findings in 























Figure 3.6 Cytoskeleton, membrane and adhesion genes are significantly upregulated or 
downregulated in patients with diabetes. (A) Cytoskeletal genes altered in the skin in patients 
with type 2 diabetes. (B) Membrane related genes that were significantly different between 


















3.3.6 CALCIUM SIGNALING AND INFLAMMATION RELATED GENES 
In the calcium-signaling gene category, we found a large increase in expression of 
KCNMA1 in patients with type 2 diabetes (Figure 3.7 A). This gene encodes the calcium- and 
voltage-dependent potassium channel KCa1.1. This channel has been implicated in rheumatoid 
arthritis, the regulation of integrins, and myoblast function170-172. We also found decreases in 
expression for the genes for striatin (STRN) and calmodulin 2 (CALM2). Calmodulin 2 is 
involved in regulating a large number of proteins through calcium-mediated mechanisms and 
striatin is a calmodulin binding protein.  
Among the significantly regulated genes to inflammation, we found a significant increase 
in the gene expression NF-κB inhibitor zeta (NFKBIZ) in patients with type 2 diabetes (Figure 
3.7 B). The protein encoded by this gene inhibits NF-κB, a key transcription factor in 
inflammation. We also found three significantly downregulated inflammatory genes including a 
receptor for IL-17 family members (IL17RA), TRAF3 Interacting Protein 2 (TRAF3IP2) and 
Interleukin 1 Receptor Like 2 (IL1RL2; IL-36 receptor). Interleukin-17A is a proinflammatory 
cytokine that promotes the recruitment of neutrophils during wound healing. In wound healing, it 
likely delays wound healing while enhancing an inflammatory response that would promote the 
removal of microbes173. TRAF3IP2 alters keratinocyte differentiation in the skin and inhibits 
response to IL-17174. Both IL-17A and tumor necrosis factor- (TNF-) are induced by IL-36 
cytokines in keratinocytes175. The cytokine IL-36 promotes wound closure through a 
mechanism involving toll-like receptor 3 (TLR3), TIR-domain-containing adapter-inducing IFN-
β (TRIF) and the transcription factor SLUG176. Thus, our findings suggest that IL17/IL36 
mediated inflammatory pathways may be altered in diabetic skin. Indeed, the IL17/IL36 
signaling axis is associated with psoriasis and targeted therapies are showing success. Psoriatic 
skin has hallmarks to some aspects of the hyperproliferative status of chronic non-healing 
wounds and comparisons between these established pathways are worthy of further investigation. 









Figure 3.7 Inflammation and calcium signaling related genes that are significantly 
upregulated or downregulated in patients with diabetes. (A) Calcium signaling related genes 
that were significantly altered between the patient groups. (B) Inflammation-related genes that 







































We examined the gene expression in the skin from patients with type 2 diabetes and non-
diabetic patients. Among the genes regulated, there were many that had been identified as being 
modulated in diabetic animals and this study serves to provide confirmation that these changes 
also occur in the skin of human patients. This information could be useful in identifying the 



























Chapter 4: Transmembrane Stem Cell Factor Protein Therapy for 
Therapeutic Angiogenesis 
4.1 INTRODUCTION  
Diabetes mellitus affects approximately 350 million people worldwide, leading to the 
death of about 4.6 million people per year2,29. As a complication of diabetes, 30 to 40 percent of 
patients age 50 and older develop peripheral artery disease (PAD)3. Severe PAD increases the 
risk of non-healing ulcers, pain from intermittent claudication and limb amputation. The current 
standard of care for PAD include surgical revascularization with bypass grafting or percutaneous 
interventions such as angioplasty, stenting and atherectomy. However, these interventions cannot 
be performed in a significant portion of patients, and many do not respond to these therapies4. An 
alternative approach for treating ischemic disease is to stimulate the body to create new 
vasculature to restore blood flow through its own regenerative processes. Several approaches 
have been attempted: the delivery of progenitor cells5,6, viral vectors to express growth 
factor/angiogenic transcription factor genes7-10 or through the delivery of growth factors11-13. 
While cell therapy is labor-intensive and gene therapy has safety issues, protein therapeutics such 
as growth factor treatments have potential advantages from delivery and safety perspectives6. 
One potential therapeutic protein for treating ischemic disease is stem cell factor (SCF), 
which signals through the receptor (c-Kit/CD117)14. The endogenous SCF isoform (SCF248) is 
initially a transmembrane protein that contains an enzyme cleavable domain allowing its release 
as soluble SCF (SCF163)15. While a major role of SCF is to maintain hematopoiesis, studies 
demonstrated that SCF induces angiogenesis, enhances recovery from stroke and improves 
recovery after myocardial infarction16-18. In many studies, SCF has a synergetic effect with G-
CSF to enhance angiogenesis and neurogenesis after stroke in animal studies17,19,20. There are 
also several clinical trials demonstrating a higher amount of peripheral blood progenitor cell 
mobilization after co-stimulation of SCF and G-CSF (Filgrastim)21,22. Though SCF seems to be a 
potential protein for ischemia treatment, various clinical studies demonstrated that patients who 
have been given SCF have a pruritic wheal and flare response at the injection23. Examination of 
these injection site reactions by transmission electron microscopy has revealed evidence of 
extensive, anaphylactic-type degranulation of dermal mast cells23. Moreover, Johnsen et al. 
reported in phase II clinical study that 13% of the patients who received the combination therapy 
 42 
of SCF and G-CSF suffered from allergic, febrile and rigor episodes, and 3% of the patients 
experienced hepatic failure24. Based on these and other findings, researchers concluded that 
phase III trials of treatments using soluble SCF were very unlikely24. 
The shorter isoform of SCF (SCF220) lacking exon 6, which encodes the cleavable 
domain and remains as a transmembrane protein, is known as transmembrane stem cell factor 
(tmSCF). Transmembrane SCF is found in the stromal cells of the bone marrow where it 
functions to support the proliferation and survival of progenitor cells25. The soluble and 
transmembrane forms of SCF differ in their properties in terms of degree of c-Kit activation, 
cellular response and adhesion between hematopoietic stem cells and the ECM14,26. Several 
reports demonstrated the advanced properties of tmSCF in comparison to SCF26. For example, 
previous reports showed that tmSCF causes prolonged activation of the c-Kit receptor than the 
soluble isoform27 and induces long term proliferation of CD34+ hematopoietic cells28.  
While soluble SCF has been studied extensively for its therapeutic properties, tmSCF has 
not been examined as a potential protein therapy. In this chapter, we explored the potential of 
tmSCF protein therapeutics. To further enhance the therapeutic efficiency, we embedded tmSCF 
in lipid nanocarriers: liposomes and nanodiscs. Liposomes are frequently used in drug or protein 
delivery due to its amphiphilic character. Lipid bilayer is hydrophobic thus enabling it to 
incorporate hydrophobic molecules such as membrane proteins between lipid bilayers. Inside of 
the lipid bilayer is filled with aqueous solution, allowing hydrophilic chemicals to be 
incorporated. In this study, we inserted tmSCF protein between lipid bilayers of liposomes, 
aiming to improve the therapeutic efficiency. Nanodiscs are also made by lipid bilayer, shaping 
in disc-like structure, allowing an access of receptor protein from both directions (front and 
back). Both formulations of lipid nanocarriers will enhance the therapeutic efficiency of tmSCF 
protein thanks to the lipid bilayers that resembles cell membrane, allowing membrane protein to 
work in its native-like environment. 
4.2 MATERIALS AND METHODS  
4.2.1 PREPARATION OF TMSCF PROTEOLIPOSOMES 
 For the production of recombinant tmSCF, HEK-293Ta cells were transduced with 
lentiviral vector with constitutive expression of 6X His tagged tmSCF. Viruses were produced in 
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HEK-293Ta cells using human lentiviral packaging system according to the manufacturer’s 
instructions (Genecopoeia). Puromycin was used to select only for transduced cells. The cells 
were lysed in a buffer containing 20mM Tris (pH 8.0), 150mM NaCl, 1% Triton X-100, 2mM 
sodium orthovanadate, 2mM PMSF, 50mM NaF, and protease inhibitors (Roche) at room 
temperature. Transmembrane stem cell factor (tmSCF) was then isolated using cobalt chelating 
column (Chelating column; GE Healthcare), and the buffer was exchanged in 1X PBS. After 
concentrating the protein solution with Centriprep concentrators (Millipore), the final working 
concentration of protein was found to be 100 µg/ml using a BCA Protein Assay kit (Thermo 
Scientific). Purity of the protein was confirmed by SDS-PAGE followed silver staining of the 
gel.  To prepare liposomes, stock solutions (10 mg mL-1) of 1,2-dioleoyl-sn-glycero-3-
phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, cholesterol, and 
sphingomyelin were prepared in chloroform. The lipids were mixed in the volumetric ratio 
2:1:1:1 in a round bottom flask and the chloroform was removed on rotary evaporator attached to 
a vacuum pump. Liposomes were resuspended in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid buffer by vortexing, sonication, and freeze thawing. Extruding device (Avanti Polar Lipids) 
with polycarbonate membranes (400 nm) was used to homogenize the liposome population. A 
mild detergent, n-octyl-β-D-glucopyranoside (1% w/v) was added to both the liposome and the 
recombinant tmSCF. The protein and liposomes were then combined and the detergent was 
removed by timed serial dilution (every 30 min, 10% dilution up to 2h), dialysis, and treatment 
with Biobeads (Biorad). The final tmSCF concentration in tmSCFPLs was 55 g/ml.  
4.2.2. PREPARATION OF TMSCF NANODISCS  
 As a lipid source, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) was used in 
this study. POPC was stored in chloroform, so we first removed chloroform by rotary evaporator. 
After that, POPC was resuspended in sodium cholate (100 mM). MSP protein was then added to 
phospholipid solution, and the detergent concentration was adjusted between 14-40 mM. This 
construct was incubated for 15 minutes at 4oC. To solubilize the membrane protein, tmSCF was 
incubated in the n-octyl-β-D-glucopyranoside (1% w/v) for 15 minutes at 4oC. After 15 minutes 
incubation of lipid construct and tmSCF protein, these were combined and incubated for 1 hour 
at 4oC. Detergent concentration during this incubation was adjusted to 20 mM with sodium 
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cholate. Finally, detergent was removed by dialysis and biobeads. The final tmSCF concentration 
in tmSCFNDs was 77 g/ml. 
4.2.3. LIPOSOME CHARACTERIZATION 
 The size and dispersion of the proteoliposomes were characterized by dynamic light 
scattering (Malvern Zetasizer Nano ZS). Calibration was performed using 54 nm polystyrene 
particles. For TEM imaging of proteoliposomes, carbon support grids (300 mesh Cu; EM 
Sciences) were treated with glow discharge at 50 mA for two minutes (Emitech K100X; Quorum 
Technologies). The samples were then applied to the grids and the excess liquid removed with a 
filter paper. 2% uranyl acetate solution was used to stain glids, and images were taken using an 
FEI Tecnai Transmission Electron Microscope (TEM). For cryo-electron microscopy imaging, 
the liposomes were plunge-frozen in liquid ethane on carbon holey film grids (R2X2 Quantifoil; 
Micro Tools GmbH, Jena, Germany). The grids were transferred to a cryo-specimen holder 
(Gatan 626) under liquid nitrogen and put in a microscope (JEOL 2100 LaB6, 200 keV), Grids 
were maintained at close to liquid nitrogen temperature during EM session (-172 to -180oC).  
4.2.4. TMSCF PROTEIN RELEASE KINETICS FROM ALGINATE BEADS 
 Purified tmSCF protein was first labeled with Alexa Fluor™ 488 Microscale Protein 
Labeling Kit (Thermo Scientific), then tmSCFPLs and tmSCFNDs were fabricated using this 
labeled protein. Equal volume of treatments and 4% sodium alginate solution were mixed, then 
the solution was extruded from a 30G needle into a 1.1% calcium chloride solution to crosslink 
for 1 hour. Protein amount was calibrated based on the protein fluorescent signal. Fabricated 
alginate beads were incubated in the 5 ml of 1% BSAPBS in plastic scintillation vial and 
incubated at 37oC. 100 µl of released protein was collected each time point and fluorescent 
intensity was measured by plate reader. The same amount of 1% BSAPBS was replaced each 
time point to compensate.   
4.2.5. TUBE FORMATION ASSAY  
 Cells were stained with cell tracker green, cultured and starved 24h prior to the 
experiment. Growth factor reduced Matrigel (Corning) were coated on the 96 well plate, and 
endothelial cells were seeded on top of it with seeding density of 4×104/well.  Treatments were 
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then added and cells incubated for 6 or 10 hours. Images were taken using a high throughput 
imaging system (Cytation 5 Cell Imaging Multi-Mode Reader; Biotek) at each time point and the 
number of loops was quantified using Photoshop (Adobe).  
4.2.6. CELL PROLIFERATION ASSAY 
Endothelial cells were passaged into a 96-well plate and cultured in low serum media 
with 2% FBS for 24h.  Treatments were then added to cells. After 24h, BrdU was added to the 
cells and proliferation was assessed 12h later using a colorimetric BrdU assay (Cell Signaling, 
Inc.).  
4.2.7. CELL MIGRATION ASSAY 
Endothelial cells were stained with cell tracker green, and passaged to confluence in 96-
well migration assay kit (Platypus).  Treatments were added for 24h before assay starts. A cell 
stopper was then removed to allow cells to migrate. Migration area and green fluorescent 
intensity were measured after 16 and 24 hours. 
4.2.8. HIND LIMB ISCHEMIA MODEL  
Prior to surgery, alginate beads containing the treatments were fabricated by mixing 
equal volume of 4% sodium alginate solution and treatments. Beads were created through 
extruding the alginate solution through a 30G needle into a 1.1% calcium chloride solution to 
crosslink for 1 hour. Wild-type mice and ob/ob mice (n = 12-13 for WT, n = 11-12 for ob/ob; 
Jackson Labs) were used in the studies. To perform the hind limb ischemia studies, mice were 
anesthetized with 2-3% isoflurane gas and a longitudinal incision was made in the inguinal 
region of the right thigh. The femoral artery was separated from the femoral vein and nerve, and 
then double ligated with 6-0 silk sutures at two locations and the artery severed at each ligation. 
Treatments were then implanted in the pocket created by the surgery and the wound was closed 
with resorbable sutures (4-0 Vicryl; Ethicon, Inc.). 
4.2.9. IMMUNOHISTOCHEMISTRY ON HUMAN SKIN  
Human skin samples were obtained from the Glasgow Caledonian University Skin 
Research Tissue Bank, Glasgow UK. The tissue bank has NHS research ethics approval to 
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supply human skin for research (REC REF: 16/ES/0069). All methods were carried out in 
accordance with relevant guidelines and regulations. All experimental protocols were approved 
by the NHS East of Scotland Research Ethics Service. Informed consent was obtained from all 
subjects (no patients were under 18 years of age). Samples were formalin fixed and embedded in 
paraffin following standard procedures prior to sectioning. The sections were then deparaffinized 
in xylene and treated for 3 hours with antigen retrieval solution (Dako) at 80°C. The sections 
were cooled to room temperature and blocked with 20% fetal bovine serum for 45 minutes and 
then immunostained overnight with 1:100 dilution of primary antibody to PECAM-1 (Cell 
Signaling), SCF (Abcam), FSP1 (Abcam), c-Kit (Abcam), and mast cell tryptase (Abcam). 
Secondary staining was performed with secondary antibodies conjugates with Alexa Fluor 488 or 
594 dye (Thermo Scientific). Following staining, the samples were imaged using confocal 
microscopy. For quantification, double-positive areas were quantified using Photoshop and 
ImageJ.  
4.2.10 IMMUNOHISTOCHEMISTRY ON MICE  
The thigh and calf muscles were formalin fixed and embedded in paraffin following 
standard procedures prior to sectioning. The sections were deparaffinized in xylene and treated 
for 3 hours with antigen retrieval solution (Dako) at 80°C. The sections were cooled to room 
temperature and blocked with 20% fetal bovine serum for 45 minutes and then immunostained 
overnight with 1:100 dilution of primary antibody to PECAM-1 (Cell Signaling), SMA 
(Abcam), CD34 (Santa Cruz), and VE-cadherin (Abcam). Secondary staining was performed 
with secondary antibodies conjugates with Alexa Fluor 488 or 594 dye (Thermo Scientific). 
Following staining, the samples were imaged using confocal microscopy. The number of small 
blood vessels was counted from the PECAM-1 positive area, and the number of matured blood 
vessels was counted from the SMA positive area. For the quantification of the double-positive 
areas of CD34 and VE-cadherin were quantified using Photoshop and ImageJ. 
4.2.11 EPC COLONY FORMATION ASSAY  
Bone marrow cells (BMCs) were harvested, and Bone marrow mononuclear cells 
(BMMNCs) were then separated by using Ficoll density centrifugation. Semisolid culture 
medium was prepared by mixing methylcellulose (MethoCult™ SF M3236; Stem Cell 
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Technologies), 15% fetal bovine serum, 50 ng/ml murine vascular endothelial growth factor, 50 
ng/ml murine basic fibroblast growth factor, 50 ng/ml murine insulin like growth factor-1, 20 
ng/ml murine interleukin- 3, 50 ng/ml murine epidermal growth factor, and 100 ng/ml stem cell 
factor in IMDM. SCF is replaced with the same concentration of tmSCF, tmSCFPL, and 
tmSCFND respectively for each treatment group. Both of the BMCs and BMMCs are adjusted to 
7×105 cells / ml, then resuspended in the semisolid culture medium. Cell medium is added to 6 
well cell culture plates and incubated for 7 days. The number of small and large colonies was 
counted by two investigators who were blinded to the experimental conditions. 
4.2.12 BONE MARROW CELL INDUCTION TO CD34-CD133+CD146+EPCS 
BMCs were harvested freshly for the experiment and cultured in DMEM high glucose 
media with 10% FBS. 100 ng/ml of SCF, tmSCF, tmSCFPLs, tmSCFNDs were added to the 
BMCs media, and cells were incubated for 30 minutes. Treatment was stopped by placing the 
cell plate on ice. Then cells are stained for CD34-Alexa647 (BD Biosciences), CD133-PE 
(BioLegend) and CD146-Alexa488 (BD Biosciences). CD34-CD133+CD146+ cells are quantified 
by FlowJo software.  
4.2.13 EPCS INDUCTION TO PERIPHERAL BLOOD  
To measure the ability of treatments to induce EPCs to peripheral blood, 240µg/kg of 
SCF, tmSCF, tmSCFPLs, and tmSCFNDs were injected subcutaneously for consecutive 4 days. 
At the end of day 4, peripheral blood was collected for EPC marker analysis. As EPCs markers, 
flk1, CD146, CD34, and CD133 were used for flow cytometry analysis.  
4.2.14 EVANS BLUE EXTRAVASATION ASSAY 
Male C57BL/6J wild-type mice were anesthetized with 2 % isoflurane and initial ear 
thickness was measured using Mitsutoyo Micrometer (Uline). 250 mL sterile-filtered 1% Evans 
blue (Sigma) in PBS was injected into the retro-orbital vein and allowed to recover. After 15 
minutes later, mice were anesthetized again and intradermally injected into the ear pinnae with 
25 mL of PBS alone (into the left ear pinna) or containing 50 mg/mL SCF, tmSCF, tmSCFPLs, 
or tmSCFNDs (into the right ear pinna) using a 1 mL syringe equipped with a 30 G x 1/2 needle. 
Two and three hours after injections, mice were anesthetized again, and ear pinnae thickness was 
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measured and photographs were taken. Three hours after injections, mice were euthanized, ear 
pinnae were harvested. Ear pinnae was incubated in 300 mL dimethyl sulfoxide (DMSO) in a 48-
well tissue culture plate for 20 hours on a shaker at room temperature. Evans blue containing 
supernatant was collected, transferred into 96-well flat-bottom plate and absorbance at 620 nm 
wavelength was measured using a plate reader.  
4.2.15 STATISTICAL ANALYSIS  
All results are shown as mean ± standard error of the mean. Comparisons between only 
two groups were performed using a two-tailed Student’s t-test.  Differences were considered 
significant at p<0.05. Multiple comparisons between groups were analyzed by two-way ANOVA 






















4.3 RESULTS  
4.3.1 DIABETIC PATIENTS HAVE REDUCED ENDOTHELIAL STEM CELL FACTOR EXPRESSION  
Our group and others have identified mechanisms of therapeutic resistance to growth 
factors65,180-183, including the loss of cell surface proteoglycans65,180,181,184-186 and expression of 
angiogenesis inhibiting growth factors182. Diabetic patients have reduced recruitment of stem 
cells to ischemic regions, circulating endothelial progenitor cells and endothelial cell 
function187,188. We examined the expression of SCF/tmSCF in skin samples from diabetic and 
non-diabetic patients to assess differences in these proteins with diabetes. We found a marked 
reduction of SCF expression in endothelial cells in the skin of type 2 diabetic (T2D) patients 
(Figure 4.1 A, B). Conversely, SCF levels were similar between the groups in skin fibroblasts 
(Figure 4.1 C, D). The expression of c-Kit in endothelial cells was higher in patients with T2D 
in comparison to non-diabetic patients (Figure 4.1 E, F). In addition, we found an increase in c-
Kit in mast cells in the skin from diabetic patients (Figure 4.1 G, H). These results support that 
there is a significant alteration in SCF and c-Kit in the skin of diabetic patients that may 





















Figure 4.1. SCF is deficient in the skin of patients with diabetes. Immunostaining was 
conducted on the skin of non-diabetic (ND) and type 2 diabetic patients (T2D). (A) 
Representative immunostaining images for PECAM and SCF. Scale bar is 300 µm. (B) 
Quantification of area of double positive area for PECAM and SCF. *p<0.05 versus nondiabetic 
group (n = 6). (C) Representative immunostaining images of FSP1 and SCF. Scale bar is 300 
µm. (D) Quantification result of double positive area of FSP1 and SCF. *p<0.05 versus 
nondiabetic group (n = 6) (E) Representative immunostaining images for PECAM-1 and c-Kit. 
Scale bar is 300 µm. (F) Quantification result of double positive area of PECAM and c-Kit. 
*p<0.05 versus nondiabetic group (n = 6). (G) Representative immunostaining images of mast 
cell tryptase and c-Kit. Scale bar is 300 µm. (H) Quantification result of double positive area of 






4.3.2 SYNTHESIS OF TRANSMEMBRANE STEM CELL FACTOR PROTEOLIPOSOMES AND 
NANODISCS 
We first created several formulations of recombinant tmSCF to test the effectiveness and 
differential response in comparison to soluble SCF. Our previous studies had identified that 
embedding transmembrane proteins in proteoliposomes can alter their therapeutic and signaling 
properties65,189. In addition, recent work has identified methods for creating lipid nanodiscs that 
are stabilized by membrane scaffolding proteins (MSPs). Thus, we aim to create two types of 
nanocarriers, tmSCF proteoliposomes and nanodiscs to deliver tmSCF effectively to ischemic 
sites (Figure 4.2 A). Transmembrane stem cell factor (tmSCF) protein was first harvested and 
purified as described in method section. SDS-PAGE, western blotting and silver staining were 
performed to analyze the purity of the final concentrated samples. The results of silver staining 
and western blotting indicate the high purity of tmSCF protein (Figure 4.2 B, C). We measured 
the size of the purified tmSCF and found that there is likely self-association/aggregation that 
gives it has a much larger size than soluble SCF (Figure 4.3 A). We fabricated tmSCF 
proteoliposomes (tmSCFPLs) using detergent depletion methods as previously described65,189. 
We confirmed the size of the liposomes before and after the addition of tmSCF (Figure 4.3 B). 
The liposomes were around 350 nm in diameter as expected from the extrusion membrane used. 
After embedding tmSCF, the size increased to 450 nm. We further verified the liposomal 
structure using TEM and cryo-EM (Figure 4.3 C). We also created nanodiscs based on 
MSP1D1. Purified nandiscs had a size of 20-30 nm and following tmSCF embedding and 
detergent depletion, the size increased to 150 nm (Figure 4.4 A). The structure of the nanodiscs 












Figure 4.2. Schematic illustration of tmSCFPLs and tmSCFNDs. Purification of tmSCF 
protein. (A) Schematic illustration of tmSCFPLs and tmSCFNDs. (B) Western Blot result of 
















Figure 4.3. Characterization of tmSCFPLs using DLS, TEM, and Cryo-EM. (A) Size 
distribution for tmSCF measured by dynamic light scattering. The average size of tmSCF was 
approximately 200 nm. (B) Size distribution for liposomes and proteoliposome with tmSCF 
measured by dynamic light scattering. The average size of tmSCFPLs were around 450 nm. 





























Figure 4.4. Characterization of tmSCFNDs using DLS, TEM, and Cryo-EM. (A) Size 
distribution for empty nanodics and nanodiscs with tmSCF. The average size of tmSCFNDs was 
around 150 nm. (B) Representative TEM and cryo-EM images of nanodiscs and tmSCFNDs. 
Scale bar is 100 nm. 
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4.3.3 TRANSMEMBRANE STEM CELL FACTOR-BASED TREATMENTS DO NOT INDUCE MAST CELL 
ACTIVATION  
A major limiter in the clinical use of soluble SCF is the activation of mast cells and 
potential induction of anaphylaxis190,191. While SCF is known to induce mast cell activation, it is 
unclear whether tmSCF shares this property or if nanocarrier encapsulation alters these 
properties. We injected mice with Evan’s blue dye and then locally injected PBS, soluble SCF, 
tmSCF, tmSCFPL or tmSCFND into the ears of the mice. After three hours, we imaged the ears 
and extracted the dye with DMSO to quantify the vascular leakage induced by the treatments. 
We found that SCF induced vascular leakage but tmSCF-based therapies did not induce this 
response (Figure 4.5). It is widely known that mast cell activation triggers histamine release, 
causing vascular leakage. Thus, our Evan’s blue extravasation assay implies that tmSCF-based 
treatments do not induce mast cell activation.  
4.3.4 TRANSMEMBRANE SCF PROTEOLIPOSOMES INDUCED GREATER ANGIOGENIC TUBE 
FORMATION IN ENDOTHELIAL CELLS THAN TRANSMEMBRANE SCF OR TRANSMEMBRANE SCF 
NANODISC  
To measure the angiogenic activity of tmSCF based therapies, we performed a tube 
formation assay on endothelial cells. While tmSCF protein itself induced limited tube formation, 
tmSCFPLs had 16 to 18 fold greater activity (Figure 4.6 A, B). In contrast, we did not see a 
significant induction of tube formation tmSCFND treatment (Figure 4.6 C, D). We also tested 
endothelial cell migration and proliferation but did not see any significant difference for any of 









Figure 4.5. Evan’s blue dye extravasation assay, showing tmSCF-based therapy had a 
minimal activation of mast cell. (A) Representative pictures of mice ears after Evan’s blue 
extravasation assay. PBS was injected to the left ear as a control and treatments were injected to 













Figure 4.6 Endothelial cell tube formation assay. (A) HUVECs were starved in MCDB131 
(Thermo Scientific) supplemented with 0.5% FBS, L-glutamine and Penicillin-Streptomycin 24 
hours prior to the experiment and treated with tmSCF or tmSCFPLs. Loop number was counted 
after 6 and 10 hours of incubation. Significantly higher numbers of loops were formed in 1 ng/ml 
and 10 ng/ml concentrations of tmSCFPLs groups compared to negative control. (B) 
Representative images of HUVECs after 6 hours of tmSCF or tmSCFPLs treatment. Scale bar is 
300 µm.  (C) HUVECs were treated with tmSCF or tmSCFNDs. No significant difference was 
confirmed in any of the treatment groups. (D) Representative images of HUVECs after 6 hours 










Figure 4.7. Endothelial cell migration and proliferation assay. (A) Quantification results of 
migration assay, HUVECs were treated by tmSCFPLs. The number of the cells migrated towards 
the center were counted by green fluorescent signals. (B) Quantification results of migration 
assay, HUVECs were treated by tmSCFNDs. The number of the cells migrated towards the 
center were counted by green fluorescent signals. (C) BrdU intensity was measured after 
HUVECs were treated by tmSCFPLs. (D) BrdU intensity was measured after HUVECs were 






4.3.5 TRANSMEMBRANE STEM CELL FACTOR PROTEOLIPOSOMES AND NANODISCS ENHANCE 
REVASCULARIZATION IN WILD TYPE MICE  
To examine whether tmSCF-based treatments could enhance revascularization, we 
ligated the femoral artery of the mice and implanted alginate beads that encapsulated treatments 
at the ischemic site. We found significantly higher relative blood flow recovery in 
tmSCFPLs/NDs groups in comparison to alginate group (Figure 4.8 A, B). 
Immunohistochemical staining for PECAM-1 and α-smooth muscle actin (α-SMA) revealed that 
there was a significant increase in small blood vessels formed at Day 14 in the tmSCFNDs 
treatment group while there was increased mature blood vessels in mice treated with tmSCFPLs 
(Figure 4.9 A-D).  
4.3.6 TRANSMEMBRANE STEM CELL FACTOR PROTEOLIPOSOMES AND NANODISCS ENHANCE 
REVASCULARIZATION IN OB/OB TYPE MICE 
To examine the effect of the treatments under diabetic conditions, we repeated the hind 
limb ischemia model on ob/ob mice. After 14 days, significantly higher blood flow recoveries 
were seen in tmSCFPLs and tmSCFNDs treated groups in comparison to an alginate only control 
(Figure 4.10 A, B). Immunohistochemical staining on ob/ob mice to detect endothelial cells 
(PECAM-1) and smooth muscle cells (αSMA) showed a higher number of small blood vessels 
under tmSCFNDs treatment while there was a higher number of matured blood vessels under 
tmSCFPLs treated group (Figure 4.11 A-D). Treatment with tmSCF alone did not enhance the 
mature blood vessel formations in ob/ob mice in comparison to WT mice, indicating the better 
treatment potential with nanocarriers. Overall, tmSCF treatment with nanocarriers improved 

































Figure 4.8. The result of hindlimb ischemia model on wild type mice. (A) Relative blood 
flow recovery after hindlimb ischemia surgery on WT mice (n =12-13). (B) Representative mice 
foot images taken by laser speckle imaging. Left foot is control (no surgery) and right foot is 
























Figure 4.9. PECAM and αSMA immunostaining on ischemic foot of WT mice. 
(A) The number of small blood vessels in the calf and thigh muscle counted from PECAM 
immunostaining images (n = 4-7). (B) The number of large blood vessels counted from αSMA 
immunostaining images (n = 4-7).  (C) Representative immunostaining images of PECAM (red) 
and αSMA (green) on WT mice calf muscle. Scale bar is 300 µm. (D) Representative 
immunostaining images of PECAM (red) and αSMA (green) on WT mice thigh muscle. Scale 


























Figure 4.10. The result of hindlimb ischemia model on ob/ob mice. (A) Relative blood flow 
recovery after hindlimb ischemia surgery on ob/ob mice (n =11-12). (B) Representative mice 
foot images taken by laser speckle imaging. Left foot is control (no surgery) and right foot is 




























Figure 4.11. PECAM and αSMA immunostaining on ischemic foot of ob/ob mice. (A) The 
number of small blood vessels in the calf and thigh muscle counted from PECAM 
immunostaining images (n = 4-10). (B) The number of large blood vessels counted from αSMA 
immunostaining images (n = 4-10). (C) Representative immunostaining images of PECAM (red) 
and αSMA (green) on ob/ob mice calf muscle. Scale bar is 300 µm. (D) Representative 
immunostaining images of PECAM (red) and αSMA (green) on ob/ob mice thigh muscle. Scale 




4.3.7 TRANSMEMBRANE STEM CELL FACTOR NANODISCS INDUCED POTENT SUBTYPES OF 
ENDOTHELIAL PROGENITOR CELLS 
 In section 4.3.4, we found enhanced tube formation of HUVECs with tmSCFPL 
treatments, indicating a potential angiogenesis of endothelial cells. In this section, we examined 
potential vasculogenesis of endothelial progenitor cells with our treatments. We first conducted 
an EPC colony formation assay. We quantified the number of small EPCs and large EPCs after 7 
days of bone marrow mononuclear cells (Figure 4.12 A). Small EPCs indicate primitive EPCs 
with highly proliferative activity, and large EPCs indicate definitive EPCs with vasculogenic 
properties. There is no significant difference in the number of small colony formation between 
groups (Data not shown). However, we confirmed a significantly higher number of large EPC 
colonies formed in SCF, tmSCFPLs and tmSCNFDs treated groups in comparison to control, 
indicating their high vasculogenic potential (Figure 4.12 B). 
We then investigated the effect of our treatment on bone marrow cells by incubating them 
with treatments for 30 minutes. We examined markers for EPCs including CD34, CD133, 
CD146, and found that tmSCFPLs and tmSCNDs increased the population of CD34-
CD133+CD146+ cells in comparison to the control or tmSCF treated cells (Figure 4.12 C). 
Notably, a population of CD34-CD133+ EPCs was identified to be the most potent EPC 
phenotype for rescuing ischemia in a recent study192, suggesting that tmSCFPLs and tmSCFNDs 
induced this potent EPC phenotype. We next immunostained for CD34+/CD144+ in the muscles 
of WT mice after the hind limb ischemia study and found increased EPCs in the ischemic 
muscles of tmSCFNDs treated mice, indicating the recruitment of EPCs to the ischemic region 
(Figure 4.13). We also immunostained for EPCs in the muscles of ob/ob mice from the hind 
limb ischemia study and found increased CD34+/CD144+ in the ischemic muscles of tmSCF 
treated mice (Figure 4.14). It is noted that the percentage of the double positive area is much 
lower in ob/ob mice, indicating the reduced effect of our treatment in ob/ob mice. Together, 
these results suggest that nanocarrier formulations of tmSCF are more active in inducing potent 








Figure 4.12. EPC colony formation assay demonstrated significantly more large EPC 
colonies by tmSCFPLs and tmSCFNDs.  (A) Representative picture of large EPC colony (Top) 
and small EPC colony (Bottom). (B) Quantification result of number of large EPC colonies per 
well. (C) Bone marrow cells are incubated with treatments for 30 minutes. tmSCFPLs and 
tmSCFNDs induced more CD34-CD133+CD146+EPCs than control. *p<0.05 versus control, 





































Figure 4.13. Immunostaining of calf and thigh muscle of WT mice after hind limb ischemia. 
(A) Representative images of calf muscle of WT mice after hind limb ischemia (Day 14). CD144 
(Green), CD34 (Red), and DAPI (Blue). Scale bar is 300 µm. (A) Representative images of thigh 
muscle of WT mice after hind limb ischemia (Day 14). CD144 (Green), CD34 (Red), and DAPI 
(Blue). Scale bar is 300 µm. (C) Quantification results of double positive area (%) of CD144 and 



























Figure 4.14. Immunostaining of calf and thigh muscle of ob/ob mice after hind limb 
ischemia. (A) Representative images of calf muscle of ob/ob mice after hind limb ischemia (Day 
14). CD144 (Green), CD34 (Red), and DAPI (Blue). Scale bar is 300 µm. (A) Representative 
images of thigh muscle of ob/ob mice after hind limb ischemia (Day 14). CD144 (Green), CD34 
(Red), and DAPI (Blue). Scale bar is 300 µm. (C) Quantification results of double positive area 
(%) of CD144 and CD34, indicating that the effect of our treatments are reduced in ob/ob mice. 
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4.3.8 TRANSMEMBRANE STEM CELL FACTOR NANODISCS INDUCED MOBILIZATION OF CD34-
CD133+EPCS TO PERIPHERAL BLOOD  
Following injury or development of ischemia, EPCs mobilize and home to the region of 
injury193. Soluble SCF is known to participate in both the mobilization and homing of EPCs in 
concert with other cytokines194. To test if the tmSCF-based treatments induced EPC 
mobilization, we performed subcutaneous injections of the treatments in mice for four days 
consecutively and then performed flow cytometry on the peripheral blood to identify EPCs. 
While we did not observe significant changes in the conventional EPC population of 
CD34+CD133+CD146+FLK1+ cells (Figure 4.15 A), we found that there were increases in 
CD34-CD133+CD146+FLK1+ and CD34-CD133+CD146+FLK1- cells in the tmSCFNDs treated 
group (Figure 4.15 B, C). This result indicates that tmSCFNDs induce mobilization of the potent 
subtypes of EPCs to peripheral blood described in previous work192. We also examined the EPC 
population in bone marrow after four consecutive days of subcutaneous injection of our 
treatments, but neither the CD34-CD133+CD146+FLK1+ nor CD34+CD133+CD146+FLK1+ 





































Figure 4.15. EPC mobilization to peripheral blood after tmSCFND treatment.  (A) 
Frequency of CD34+CD133+CD146+FLK1+ cells in peripheral blood after subcutaneous 
injection (n = 11-12). (B) Frequency of CD34-CD133+CD146+FLK1+ cells in peripheral blood 
after subcutaneous injection (n = 10-13). (C) Frequency of CD34-CD133+CD146+FLK1- cells in 
peripheral blood after subcutaneous injection (n = 10-13). (D) CD34-CD133+CD146+FLK1+ 
subpopulation in bone marrow was analyzed after four days of subcutaneous injection of our 
treatment. (E) CD34+CD133+CD146+FLK1+ subpopulation in bone marrow was analyzed after 
four days of subcutaneous injection of our treatment.*, †, ‡ and § indicate significant difference 
over alginate control, tmSCF, tmSCFPL, and SCF, respectively (p < 0.05; Kruskal–Wallis one-





The treatment of ischemia in diabetes has been a recurrent clinical problem, especially 
among diabetic patients receiving bypass surgery or percutaneous interventions for limb 
ischemia who have significantly worse outcomes than non-diabetic patients.195,196 To examine 
abnormal protein expression in type 2 diabetic patients, we first conducted immunostaining on 
the skin of type 2 diabetes. Our data revealed significantly reduced SCF expression while 
upregulated c-Kit expression in endothelial cells of type 2 diabetes (Figure 4.1). There may be a 
feedback mechanism behind these phenomena. According to the previous study, Ets homologous 
factor (Ehf), a member of the Ets family transcription factors, is upregulated by TGF-b/Smad 
signaling in mouse bone marrow–derived mast cells, which reduces the expression of c-Kit on 
mast cell.197 It may be possible that regulation of Ehf transcription factor may be disrupted in 
type 2 diabetes, thus causing abnormal c-Kit expression in mast cell. 
Surgeries or percutaneous interventions for limb ischemia on diabetic patients may lead 
to the recurring occurrence of limb ischemia, thus our lab aims to develop a protein therapy 
using tmSCF protein. While soluble form of SCF has been explored as a therapy for multiple 
indications, its pleiotropic effects including mast cell activation and induction of anaphylaxis 
have prevented SCF from being adopted for clinical use. Our study supports that local delivery 
of tmSCF protein may be a viable alternative to soluble SCF for limb ischemia and does not 
activate mast cells. Evan’s blue extravasation assay demonstrated that all of tmSCF, tmSCFPLs, 
and tmSCFNDs did not induce vascular leakage, indicating little or no mast cell activation.  
(Figure 4.5).  
Our hind limb ischemia model on WT demonstrated that tmSCFPLs and tmSCFNDs 
increased relative blood flow recovery significantly more than control group (Figure 4.8). Our 
immunostaining results on the calf and thigh muscle after hindlimb ischemia surgery showed a 
significantly more of small blood vessels formation after tmSCFNDs treatment and matured 
blood vessels formation after tmSCFPLs treatment. These results suggest that tmSCFPLs may 
enhance remodeling of pre-existent arterioles and maturing blood vessels, and tmSCFNDs 
enhanced de novo blood vessels formation possibly by EPCs. Hind limb ischemia study on ob/ob 
mice also showed a similar trend. We confirmed increased blood flows on tmSCFPLs and 
tmSCFNDs groups at day 14 (Figure 4.10), and significantly more of small blood vessel 
formations by tmSCFND and mature blood vessel formations by tmSCFPLs (Figure 4.11). 
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Our endothelial tube formation assay demonstrated an enhanced tube formation only by 
tmSCFPLs (Figure 4.6). It is generally known that low density lipoprotein (LDL) is 
preferentially taken up by endothelial cells. The structure of proteoliposome may resemble that 
of LDL, which may lead to the preferential enhancement of endothelial tube formation by 
tmSCFPLs. Our EPC mobilization assay also demonstrated increased EPC mobilization 
exclusively by tmSCFND. The reason why EPCs respond to tmSCFNDs remains unknown. 
However, High Density Lipoprotein (HDL) which is structurally similar to nanodisc is known to 
enhance mobilization of EPCs. These observations may support a claim that the type of 
nanocarrier used to deliver tmSCF elicited a differential response based on cell type. 
Our EPC mobilization assay showed a significantly higher number of CD34-
CD133+EPCs in peripheral blood after subcutaneous injection of tmSCFNDs in comparison to 
control (Figure 4.15). CD34-CD133+EPCs are unconventional type of EPCs, but it is suggested 
to be a potent subtype of EPCs192.  Friedrich et al. demonstrated that homing ability of CD34-
CD133+EPCs are significantly higher than that of CD34+CD133+EPCs. Moreover, CD34-
CD133+EPCs injection significantly reduces the lumen circumference and neointima formation 
after vascular injury. Interestingly, we confirmed a significantly higher amount of CD34+EPCs at 
ischemic limb in tmSCFNDs treated group (Figure 4.13, 14). Previous studies demonstrated that 
CD34+EPCs are more matured and adherent than CD34-EPCs, which can be found in stable 
plaques192,198. Considering our findings and others, tmSCFNDs may induce CD34-EPCs to 
peripheral blood, then these EPCs become mature at ischemic site of injury. 
4.5 CONCLUSION 
 In this chapter, we developed a tmSCF protein therapy. Two types of nanocarriers, 
liposomes and nanodiscs, were used to enhance the functional activities of tmSCF protein. Hind 
limb ischemia model on WT and ob/ob mice demonstrated that tmSCFPLs and tmSCFNDs 
significantly increased the blood flow recovery. Endothelial tube formation assay suggested that 
tmSCFPLs may have an angiogenic potential on endothelial cells. EPC mobilization assay 
revealed that tmSCFNDs significantly induced the number of CD34-CD133+EPCs in peripheral 
blood, indicating the vasculogenic potential of tmSCFNDs. These results suggest that we may be 
able to achieve targeted protein delivery to a specific cell type by controlling nanocarriers.  
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Chapter 5: Endocytosis and Signaling Mechanism in tmSCF Protein Therapy  
5.1 INTRODUCTION  
Previous section demonstrated the alteration of mast cell activation in SCF and tmSCF-
based therapy while maintaining angiogenic ability in endothelial cells and EPCs. In this chapter, 
we demonstrate cellular mechanistic studies to elucidate the functional difference. In mast cell, 
SCF and tmSCF interact with their cognate receptor c-Kit, leading to dimerization, signaling and 
internalization through either a clathrin or caveolin-mediated endocytosis199,200. Clathrin-
mediated endocytosis is the most well studied endocytosis pathway, where clathrin proteins 
assemble to form a clathrin-coated pit followed by budding of the pits away from a surface 
membrane, bringing receptor to endosomes. Reaction rate of clathrin-mediated endocytosis is 
faster (Rate constant, Ke = 0.2 - 0.4 min
-1) in comparison to clahtrin independent endocytosis (Ke 
= 0.05 - 0.1 min-1)201. Previous study suggested that clathrin-mediated endocytosis leads to 
increased proliferation and migration of mast cells202. Another major endocytosis pathway is 
caveolin-mediated endocytosis. This endocytosis has slower uptake kinetics and leads to reduced 
proliferation and migration of mast cell202. Based on these studies, we hypothesized that mast 
cells use caveolin to uptake tmSCF-based therapies, thus attenuating mast cell degranulation and 
preventing anaphylaxis. On the other hand, mast cells use clathrin to uptake SCF, causing mast 
cell degranulation. To examine this hypothesis, we measured the colocalization of clathrin or 
caveolin with c-Kit to examine which endocytosis mechanism cells use to uptake protein 
therapies.  
Other than endocytosis, signaling downstream of the c-Kit receptor also influences 
functional activities of cells. The main signaling pathway downstream of c-Kit is 
Phosphoinositide 3-kinase (PI3K) pathway, mitogen-activated protein kinase (MAPK) pathway, 
and signal transducers and activators of transcription (STAT) pathway. In general, 
phosphorylation of c-Kit activates PI3K, leading to the phosphorylation of AKT, activating 
mTOR, ultimately contributing to cell survival. Phosphorylation of c-Kit also activates RAS 
GTPase, causing ERK phosphorylation and leading to increased cell proliferation203.  
Dimerization of c-Kit receptor activates Janus Kinase (JAK), which phosphorylates STATs, 
allowing STATs to translocate into the nucleus where they act on target gene promoters. STAT5 
contributes to mast cell homeostasis by mediating proliferation, survival, and mediator release204. 
 73 
Such that, signaling downstream of c-Kit leads to critical cellular activities. In this chapter, we 
will first closely examine the endocytosis mechanism of mast cell, EPCs, and endothelial cells to 
figure out what may cause the activation differences in SCF and tmSCF-based therapy. Later in 
this chapter, we will investigate the signaling pathway downstream of c-Kit in mast cell and bone 
























5.2 MATERIALS AND METHODS  
5.2.1 C-KIT INTERNALIZATION BY FLOW CYTOMETRY 
MC9 mast cells, bone marrow cells, and HUVECs were starved overnight with 0.5% 
serum prior to the experiment. The cells were treated with Brefeldin A (5 µg/ml; Cayman 
Chemicals, Inc.) for 2 hours to inhibit a repopulation of surface c-Kit. For clathrin and caveolin 
inhibitor study, we treated cell with 25nM of nystatin (caveolin inhibitor) for 30 minutes, 100 
nM of wortmannin (clathrin inhibitor) for 15 minutes, and pitstop (clathrin inhibitor) for 10 
minutes before tmSCF treatments. The cells were washed with 37Co HEPEs buffer (10 mM 
HEPES, 137 mM NaCl, 2.7 mM KCl, 0.4 mM Na2HPO4⋅7H2O, 5.6 mM glucose, 1.8 mM 
CaCl2⋅2H2O, and 1.3 mM MgSO4⋅7H2O with 0.04% BSA) and resuspended at 5 × 105 cells/ml 
in HEPES buffer without BFA. The cells were then treated with either of SCF, tmSCF, 
tmSCFPLs, and tmSCFNDs (100 ng/ml) for 5, 10, 20, and 30 minutes. After the treatment, cells 
were plunged into ice to stop the c-Kit internalization. For HUVECs, accutase was used to 
detach cells. The surface c-Kit was stained with PE-Cy™7 anti-Mouse CD117 antibody (BD 
Biosciences) or PE-Cy7 anti-Human CD117 antibody (Biolegend) then surface c-Kit intensity 
was read by flow cytometry. Population above the intensity of 104 was calculated. The surface c-
Kit intensity was normalized to initial time point (0 min).   
5.2.2 CLATHRIN, CAVEOLIN AND C-KIT COLOCALIZATION ASSAY 
Prior to the experiment, bone marrow cells were harvested from 10 weeks old female 
C57BL/6J wild-type mice and mononuclear cells are isolated by Ficoll density centrifugation. 
These bone marrow mononuclear cells are cultured for seven days under endothelial media to 
induce spindle shaped adherent EPCs. The EPCs, MC9 mast cells, and HUVECs were starved 
overnight with 0.5% serum prior to the experiment. 100 ng/ml of SCF, tmSCF, tmSCFPLs and 
tmSCFNDs were then treated for two minutes and immediately plunged into ice to stop the 
internalization. After washing with PBS, and fixing with 4% PFA, immunostaining with clathrin 
(Abcam), caveolin (Abcam) and c-Kit (Invitrogen, NOVUS Biological) were conducted. Images 
of 30 cells are taken by confocal microscopy and we analyzed the colocalization of clathrin and 
c-Kit and caveolin and c-Kit by coloc 2 in Image J. Pearson’s R value was used for analysis. 
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5.2.3 IMMUNOSTAINING OF PHOSPHOR-C-KIT  
Prior to the experiment, the cells were starved overnight with 0.5% serum prior to the 
experiment. 100 ng/ml of SCF, tmSCF, tmSCFPLs and tmSCFNDs were then treated for five 
minutes and immediately plunged into ice to stop the phosphorylation. After washing with PBS, 
and fixing with 4% PFA, immunostaining with p-c-Kit (R&D) and c-Kit (Invitrogen, NOVUS 
Biological) were conducted. Images of 30 cells are taken by confocal microscopy and we 
analyzed the mean intensity of p-c-Kit inside of a single cell by photoshop.  
5.2.4 FLOW CYTOMETRY OF P-AKT, ERK, STAT1, STAT5 IN MC9 MAST CELL AND BONE MARROW 
MONONUCLEAR CELLS 
Prior to the experiment, the cells were starved overnight with 0.5% serum prior to the 
experiment. 100 ng/ml of SCF, tmSCF, tmSCFPLs and tmSCFNDs were then treated for five 
minutes and immediately plunged into ice to stop the phosphorylation. After washing with PBS 
with sodium orthovanadate, cells are permeabilized with 100% methanol for 10 minutes 
followed by fixation with 4% paraformaldehyde for 10 minutes.  Antibodies to PE anti-mouse p-
AKT (BD Biosciences), Alexa fluor 647 anti-mouse p-ERK(BD Biosciences), Pacific Blue anti-
mouse p-STAT1 (BD Biosciences), PE-cy7 anti-mouse p-STAT5 (BD Biosciences) are used and 
cells were stained for 30 minutes on ice. The intensities of phosphor-proteins were read by flow 
cytometry. Median intensity of the population above 103 was quantified using FlowJo.  
5.2.5 STATISTICAL ANALYSIS  
All results are shown as mean ± standard error of the mean. Comparisons between only 
two groups were performed using a two-tailed Student’s t-test.  Differences were considered 
significant at p<0.05. Multiple comparisons between groups were analyzed by two-way ANOVA 







5.3 RESULTS  
5.3.1 TRANSMEMBRANE SCF-BASED TREATMENTS CAUSE SLOWER C-KIT INTERNALIZATION 
SCF interacts with its cognate receptor c-Kit leading to dimerization, signaling and 
internalization through either a calveolin or clathrin-mediated pathway199. We next examined 
how tmSCF and its nanocarrier formulations altered its uptake by the c-Kit receptor. We 
measured the surface c-Kit internalization by flow cytometry and found that tmSCF-based 
treatments had slower uptake in mast cells (MC9 cells), bone marrow mononuclear cells 
(BMMNCs) and endothelial cells in comparison to soluble SCF (Figure 5.1 A-C). In endothelial 
cells, the internalization of c-Kit was the fastest for the proteoliposomal formulation (tmSCFPLs) 
in comparison to other tmSCF formulation but still significantly slower than soluble SCF 
(Figure 5.1 C).  
5.3.2 TRANSMEMBRANE SCF FORMULATIONS ALTER THE UPTAKE MECHANISMS IN MAST 
CELLS, EPCS, AND ENDOTHELIAL CELLS 
Previous studies have shown that there are two pathways of uptake for SCF in mast 
cells202. One uptake pathway is mediated by caveolin. This pathway has slower uptake kinetics 
and leads to reduced proliferation and migration of mast cell202. The alternative pathway is 
mediated by clathrin, has faster uptake kinetics, and leads to increased proliferation and 
migration of mast cells202. To examine the uptake mechanism of the tmSCF formulation, we 
treated cells with SCF and the tmSCF-based treatments and then performed immunostaining for 
c-Kit and clathrin or calveolin followed by an analysis for co-localization between the markers. 
We found that mast cells preferentially use clathrin to internalize SCF and caveolin to internalize 
tmSCFNDs (Figure 5.2). Mast cells use both clathrin and caveolin to uptake tmSCF or 
tmSCFPL. These results correspond well with the protein uptake kinetics results, showing the 
faster uptake by SCF (a hallmark of clathrin-mediated uptake202) and slower uptake of tmSCF-
based therapy (a hallmark of caveolin mediated uptake; Figure 5.1).  
Next, we conducted the same experiment on bone marrow derived EPCs and found that 
early EPCs preferentially use clathrin to uptake SCF while they use caveolin to uptake tmSCF, 
tmSCFPLs and tmSCFNDs (Figure 5.3). We found that endothelial cells use both clathrin and 
caveolin to uptake SCF, tmSCF, tmSCFPLs and tmSCFNDs (Figure 5.4). These results indicate 
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that the different cell types use different uptake mechanisms. Most notably, mast cells appear to 
preferentially use clathrin to uptake SCF and caveolin to uptake tmSCF formulations, which may 
be the key difference why we see mast cell degranulation in SCF treatment but not in tmSCF-
based treatments.  
5.3.3 TRANSMEMBRANE SCF-BASED THERAPIES ACTIVATE C-KIT PATHWAY ENDOTHELIAL 
CELLS AND EPCS BUT NOT MAST CELLS 
To elucidate the mechanism of c-Kit/SCF signaling pathway upon SCF or tmSCF-based 
treatments, we examined the phosphorylation of c-Kit by SCF or tmSCF-based treatments by 
immunostaining of p-c-Kit. In MC9 mast cells, we found that SCF leads to a significantly higher 
c-Kit phosphorylation than tmSCF-based treatments (Figure 5.5). Next, we examined the degree 
of phosphorylation on early EPCs and found that SCF and tmSCFNDs treatments lead to a 
significantly higher c-Kit phosphorylation than control, indicating that SCF and tmSCFNDs may 
have angiogenic activity related to SCF/c-Kit pathway of early EPCs (Figure 5.6). Lastly, we 
conducted a parallel experiment on endothelial cells and found that SCF, tmSCF, tmSCFPLs and 
tmSCFNDs lead to a significantly higher c-Kit phosphorylation than control in endothelial cells 
(Figure 5.7). These results support that there is lower pleiotropic activity from tmSCF treatments 
on mast cells because of their minimal phosphorylation induction of c-Kit in mast cell. In 
addition, the type of formulation used for delivering tmSCF tailors its trophic specificity, with 
preferential activation and faster internalization of tmSCFPLs by matured endothelial cells and 





































Figure 5.1 c-Kit uptake measurement by flow cytometry on mast cell, endothelial 
progenitor cells, and endothelial cells. (A) Surface staining for c-Kit on MC9 mast cells was 
monitored by flow cytometry. The intensity was normalized to 0 min time point to evaluate the 
treatment uptake kinetics (n = 6). (D) Surface c-Kit on bone marrow mononuclear cells were 
monitored by flow cytometry (n = 3-6). (E) Surface c-Kits on HUVECs were monitored by flow 




Figure 5.2 c-Kit and clathrin/caveolin colocalization on MC9 mast cell. (A) Representative 
pictures of single mast cell stained with clathrin and c-Kit. (B) Pearson’s R value of the 
colocalization of clathrin and c-Kit (n = 30). (C) Representative pictures of single mast cell 
stained with caveolin and c-Kit. (D) Pearson’s R value of the colocalization of caveolin and c-Kit 






Figure 5.3 c-Kit and clathrin/caveolin colocalization on endothelial progenitor cell. (A) 
Representative pictures of EPCs stained with clathrin and c-Kit. (B) Pearson’s R value of the 
colocalization of clathrin and c-Kit (n = 30). (C) Representative pictures of EPCs stained with 
caveolin and c-Kit. (D) Pearson’s R value of the colocalization of caveolin and c-Kit (n = 30). 








Figure 5.4 c-Kit and clathrin/caveolin colocalization on endothelial cells (HUVECs). (A) 
Representative pictures of endothelial cells stained with clathrin and c-Kit. (B) Pearson’s R value 
of the colocalization of clathrin and c-Kit (n = 30). (C) Representative pictures of endothelial 
cells stained with caveolin and c-Kit. (D) Pearson’s R value of the colocalization of caveolin and 









Figure 5.5 Phosphorylation of c-Kit on MC9 mast cell. (A) Representative pictures of  
single mast cell stained with p-c-Kit and c-Kit. Scale bar is 30µm. (B) The mean p-c-Kit 



















Figure 5.6 Phosphorylation of c-Kit on endothelial progenitor cells. (A) Representative 
pictures of EPCs stained with p-c-Kit and c-Kit. Scale bar is 30µm. (B) The mean p-c-Kit 



















Figure 5.7 Phosphorylation of c-Kit on endothelial cells. (A) Representative pictures of 
HUVECs stained with p-c-Kit and c-Kit. (B) The mean p-c-Kit intensity inside of a single cell 



















5.3.4 INHIBITOR STUDIES FURTHER CONFIRMED ENDOCYTOSIS MECHANISMS IN ENDOTHELIAL 
CELLS 
To further confirm whether endothelial cells use clathrin- or caveolin-mediated 
endocytosis to uptake protein therapy, we used a caveolin inhibitor (Nystatin) and a clathrin 
inhibitor (Wortmannin) to inhibit the either endocytosis, and measured the surface c-Kit on 
HUVECs. We treated cells with Breferdin A to stop c-Kit repopulation, then treated cells with 
drugs to inhibit the either endocytosis pathway. After 30 minutes of incubation with SCF, 
tmSCF, tmSCFPLs, or tmSCFNDs, we measured the surface c-Kit intensity by flow cytometry. 
Surface c-Kit intensity was normalized to time zero c-Kit intensity. With nystatin treatment, 
tmSCFPLs treated HUVECs showed a significantly increased surface c-Kit in comparison to the 
group without nystatin treatment (Figure 5.7 A). With wortmannin treatment, both SCF and 
tmSCFPLs treated HUVECs showed a significantly increased surface c-Kit in comparison to the 
group without wortmannin treatment (Figure 5.7 B). These results indicate that endothelial cells 
use both caveolin- and clathrin-mediated endocytosis to uptake tmSCFPLs, and they use 




















Figure 5.8 c-Kit uptake study with nystatin and wortmannin. (A) The amount of surface c-
Kit was measured after 30 minutes treatment of SCF, tmSCF, tmSCFPLs, or tmSCFNDs with 
and without nystatin treatment. (B) The amount of surface c-Kit was measured after 30 minutes 

















5.3.5 C-KIT DOWNSTREAM SIGNALING 
 We examined the degree of phosphorylation on c-Kit receptors after treatments in the 
previous section. In this section, we further investigated the downstream signaling of c-Kit 
including PI3K pathway, MAPK pathway, and STAT pathway. In general, phosphorylation of c-
Kit activates PI3K, leading to the phosphorylation of AKT, activating mTOR, ultimately 
contributing to cell survival. Phosphorylation of c-Kit also activates RAS GTPase, causing ERK 
phosphorylation, leading to increased cell proliferation. Dimerization of c-Kit receptor activates 
JAK, which phosphorylates STATs, allowing STATs to translocate into the nucleus where they 
act on target gene promoters. 
 We first investigated the degree of phosphorylation in mast cells over time. MC9 cells 
were treated with SCF, tmSCF, tmSCFPLs, or tmSCFNDs for one, five, ten, and 15 minutes then 
plunged into ice to stop phosphorylation. As expected, SCF leads to a significantly higher 
phosphorylation of ERK, AKT, and STAT1 while tmSCF-based treatments did not induce 
phosphorylation of these downstream signaling molecules (Figure 5.9). Next, we repeated the 
same experiment on bone marrow mononuclear cells and found that tmSCFNDs induced 
significantly higher degrees of phosphorylation of ERK, AKT, and STAT1 (Figure 5.10). This 
result corresponds well with our EPC mobilization assay (Figure 4.15), suggesting that 
tmSCFNDs might preferentially work on bone marrow derived EPCs to enhance proliferation 


















Figure 5.9 Phosphorylation of ERK, AKT, STAT1 in MC9 mast cell after treatments. (A) 
Normalized p-ERK intensity was quantified from flow cytometry. Significantly higher median 
intensity of p-ERK was observed by SCF treatment at one and five minutes time point. (B) 
Normalized p-AKT intensity was quantified from flow cytometry. Significantly higher median 
intensity of p-AKT was observed by SCF treatment at five and 15 minutes time point. (C) 
Normalized p-STAT1 intensity was quantified from flow cytometry. Significantly higher median 
intensity of p-STAT1 was observed by SCF treatment at one, five and ten minutes time point. 

















Figure 5.10 Phosphorylation of ERK, AKT, STAT5 in bone marrow mononuclear cells 
after treatments. (A) Normalized p-ERK intensity was quantified from flow cytometry. 
Significantly higher median intensity of p-ERK was observed by tmSCFNDs treatment at five 
minutes time point. (B) Normalized p-AKT intensity was quantified from flow cytometry. 
Significantly higher median intensity of p-AKT was observed by tmSCFNDs treatment at ten 
minutes time point. (C) Normalized p-STAT5 intensity was quantified from flow cytometry. 
Significantly higher median intensity of p-STAT5 was observed by tmSCFNDs treatment at one 














5.3.6 PROPOSED DIAGRAM  
Overall, this study demonstrated a potential use of tmSCF as a therapeutic protein for 
PAD treatment. The major negative pleiotropic activity of mast cell activation was not observed 
on the tmSCF-based treatments. A major difference in the tmSCF-based treatments in 
comparison to soluble SCF was the slower uptake kinetics and preferential trophism of tmSCF 
based on the nanocarrier for either endothelial cells or EPCs. Mast cells use clathrin to uptake 
SCF (small size protein), and caveolin to uptake tmSCF-based treatments (large size 
protein/lipids), causing different physiological responses such as vascular permeabilization 
(Figure 4.5). In cellular level, this hypothesis is supported by the protein uptake kinetics, 
showing the fast uptake by SCF and the slow uptake by tmSCF-based treatments (Figure 5.11 
A). We also revealed that, depending on the nanocarriers to use, different cell types respond 
differently to tmSCF-based therapeutics. When liposomes are used as the carriers for tmSCF, 
endothelial cells respond and enhance tube formation and angiogenesis while no tube formation 
was observed when endothelial cells were treated with tmSCFNDs (Figure 5.11 B). When 
nanodisc is used as a carrier for tmSCF protein, EPCs respond, enhancing colony formation and 
mobilization of CD34-CD133+EPC to peripheral blood, and therapeutic angiogenesis (Figure 
5.11 C). Our study suggested that caveolin seems to be the key to uptake relatively large size 
protein-lipid therapeutics. Previous studies reported that caveolin is used to endocytose low 
density lipoprotein205-207 which may be resembled with our protein-lipid therapeutics in structure. 
This may explain why mast cells or EPCs preferentially use caveolin to uptake our protein-lipid 












Figure 5.11 Summary diagram. (A) Mast cells use clathrin to uptake SCF (fast uptake), 
causing degradation and anaphylaxis, while they use caveolin/clathrin to uptake tmSCF-based 
treatments (slow uptake), reducing the degradation and anaphylaxis. (B) Endothelial cells use 
both clathrin and caveolin to uptake SCF (fast uptake), triggering tube formation of endothelial 
cells. Endothelial cells use both of clathrin and caveolin to uptake tmSCFPL (medium speed 
uptake), triggering tube formation of endothelial cells and therapeutic angiogenesis. (C) EPCs 
use clathrin to uptake SCF (fast uptake), triggering colony formation of EPC. EPCs use caveolin 
to uptake tmSCF-based treatments (slow uptake), leading to colony formation and angiogenesis. 
Treatment with tmSCFND further induced CD34-CD133+EPC peripheral blood mobilization in 








While SCF has been explored as a therapy for multiple indications, its pleiotropic effects 
including mast cell activation and induction of anaphylaxis have prevented SCF from being 
adopted for clinical use. In chapter 4, we demonstrated that local delivery of tmSCF protein did 
not induce mast cell activation while maintaining its ability to revascularize blood flow. We 
hypothesized that different protein uptake mechanisms may explain the activation differences of 
SCF and tmSCF. 
We found that mast cells use clathrin-mediated endocytosis to uptake SCF while they use 
caveolin-mediated endocytosis to uptake tmSCF-based treatments. One potential explanation for 
the differences in uptake may be the size of the therapeutic compound. A previous study 
demonstrated that cells use clathrin-mediated pathway to take up smaller particles (< 200 nm) 
while they use caveolin-mediated pathway to take up larger particles (around 500 nm)208. Based 
on our DLS measurements (Figure 4.3), tmSCF aggregates when not in a lipid nanocarrier and 
consequently has a much larger size than soluble SCF. The larger size of tmSCF formulations 
may drive cells to use preferentially caveolin-mediated endocytosis. Consistent with this 
concept, our result showed that MC9 mast cells mainly use clathrin-mediated endocytosis to 
uptake SCF while they use caveolin-mediated endocytosis to uptake tmSCF-based treatments. 
Another hallmark of clathrin-mediated endocytosis is that it possesses fast uptake kinetics 
compared to caveolin’s slower uptake kinetics209,210. Our c-Kit internalization results on mast 
cells also support this phenomenon. The c-Kit receptor was taken up much faster when mast cells 
were treated with SCF in comparison to tmSCF-based therapy. Significantly higher 
phosphorylation of c-Kit was also observed when mast cells were treated with SCF but it is 
greatly reduced when they were treated with tmSCF-based treatments. These results imply that 
mast cells use clathrin-mediated endocytosis to uptake SCF, which triggers the activation of the 
c-Kit/SCF pathway and leads to higher vascular permeability while they use caveolin-mediated 
endocytosis to uptake tmSCF-based treatments with slow kinetics, suppressing the c-Kit/SCF 
activation and mast cell activation.  
Size of protein treatments may not be the only reason for cells to choose the pathway for 
endocytosis. Caveolin serves an important role in lipid metabolism. For example, caveolin-1 in 
adipocytes binds to fatty-acid and supports the formation of lipid droplets (intracellular 
organelles specialized for lipid storage). Another evidence of linking caveolin and lipid 
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metabolism is that Cav1-knockout mice are resistant to diet-induced obesity and show decreased 
adiposity as well as decreased levels of free cholesterol in adipocytes. Previous studies also 
reported that caveolin is used to endocytose low density lipoproteins205-207 whose structure may 
resemble our protein-lipid therapeutics. From these observations, it may be possible that 
caveolae may have a strong affinity to lipid carriers, leading to a preferential endocytosis of 
lipid-based therapies. 
 The size of the drug and lipid may be the main reasons why cells use different uptake 
mechanisms. However, the relationship of endocytosis and c-Kit downstream signaling is still 
unclear. It is possible that caveolin-mediated endocytosis does not activate the c-Kit downstream 
signaling in mast cells. One interesting hypothesis is that caveolin-mediated endocytosis 
enhances the ubiquitination of c-Kit receptors, stopping the downstream signaling cascade. 
Previous study on TGF-β receptors revealed that TGF-β receptors enter cells via lipid 
rafts/caveolae, which facilitates the ubiquitination of TGF-β receptor, leading to the degradation 
of TGF-β receptors and therefore turnoff of TGF-β signaling211. There is an adaptor protein 
called Src-like-adaptor protein (SLAP), which regulates ubiquitination of c-Kit, thus controlling 
phosphorylation of c-Kit212. Therefore, it is possible that tmSCF-based treatments let c-Kit 
receptors enter the raft/caveolae, which triggers ubiquitination of c-Kit by SLAP, turning off 
SCF/c-Kit signaling. Other than SLAP adaptor protein, c-Kit also interacts with several ubiquitin 
ligases, such as Cbl and SOCS6, or through indirect association of Cbl through Grb2212. It should 
be worth looking into the interaction between these ubiquitin ligases or adaptor proteins for c-Kit 
and raft/caveolae domain in the future work. Another hypothesis is that caveolin binds to the 
tyrosine kinase domain of c-Kit, inactivating the phosphorylation. Couet et al. demonstrated that 
the caveolin scaffold domain of caveolin-1 binds to the tyrosine kinase domain of EGF receptor, 
suppressing the phosphorylation of EGF receptor213. Receptor c-Kit and EGF are both receptor 
tyrosine kinases, thus it is possible that caveolin binds to c-Kit, inactivating the phosphorylation 
of tyrosine kinase on c-Kit.  
Our results also indicate that we will be able to target certain cell type to enhance protein 
therapy by choosing a right nanocarrier.  Proteoliposomal formations of tmSCF are internalized 
with faster kinetics and are more active in inducing tube formation in endothelial cells in 
comparison to free tmSCF or tmSCFNDs. Our group has used proteoliposomal formulations to 
deliver pro-angiogenic molecules65,180,181,184-186. Our trafficking studies performed here support 
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that there is preferential uptake of proteoliposomal formulations in mature endothelial cells in 
comparison to the other formulations and may be advantageous for endothelial targeted 
therapies. In contrast, tmSCFNDs are more active in inducing EPCs in vitro and in vivo. While 
MSP-based nanodiscs have been used for performing protein analysis and NMR of purified 
proteins214,215, they have had little exploration for use in for protein delivery applications. Our 
findings indicated that nanodisc formulations of tmSCF enhanced mobilization, colony 
formation, and homing of EPCs, thus it may be advantageous for EPC targeted therapies.  
5.5 CONCLUSION 
In this chapter, we further investigated the difference in the endocytosis mechanisms of 
SCF and tmSCF-based treatments. Our colocalization assay demonstrated that mast cells use 
clathrin-mediated pathway to uptake SCF while they use caveolin-mediated pathway to uptake 
tmSCF-based treatments. Size of the protein therapies may be the main factor to drive them to 
either types of endocytosis. Larger proteins or protein complexes (200 - 500 nm) go through 
caveolin-mediated endocytosis and smaller proteins (< 200 nm) go through clathrin-mediated 
endocytosis. SCF-c-Kit complex going through caveolin-mediated endocytosis leads to reduced 
proliferation and migration of mast cells. Conversely, SCF-c-Kit complex going through 
clathrin-mediated endocytosis results in increased proliferation and migration of mast cells, 
leading to anaphylaxis.  
We can also target a certain cell type to enhance protein therapy by choosing a right 
nanocarrier. Proteoliposomal formulations of tmSCF are internalized with faster kinetics and are 
more active in inducing tube formation in endothelial cells in comparison to free tmSCF or 
tmSCFNDs. Nanodisc formulations of tmSCF enhanced mobilization, colony formation, and 









Chapter 6: Conclusion 
6.1 CONCLUSION 
In summary, this study demonstrates the first use of tmSCF as a therapeutic protein for 
the treatment of peripheral ischemia. Our work supports that there is minimal mast cell activation 
by tmSCF-based therapies and that the activity can be targeted to specific cell types through the 
use of different nanocarriers. While both nanodisc and proteoliposome-delivered tmSCF are 
beneficial in treating ischemia, our work supports that the proteoliposomal tmSCF may act 
through the stimulation of angiogenesis in endothelial cells and proliferation of bone marrow 
cells. Conversely, nanodisc delivered tmSCF acts primarily through the mobilization and 
recruitment of bone marrow cells and stimulation of a CD34- EPC population. Overall, our work 
suggests some of the benefits of SCF treatment can be recapitulated using tmSCF therapies and 
these appear to have improved safety as well as tailorable activity based on the lipid nanocarrier 
used. 
 
6.2 FUTURE WORK 
6.2.1 ENDOCYTOSIS MECHANISM WITH INHIBITORS, AND ITS INTERACTION WITH SIGNALING 
PATHWAYS 
Due to the COVID-19 outbreak, I could not finish the inhibitor studies with clathrin or 
caveolin blockers in chapter 5. Wortmannin is a PI3K inhibitor, indirectly blocking clathrin-
mediated endocytosis. Therefore, wortmannin may not be specific to clathrin. Thus, we would 
like to try Pitstop that is more specific to clathrin. We will also try these inhibitor studies on mast 
cells and EPCs to examine if we see the similar outcome with the immunostaining studies 
conducted in the section 5.3.2. 
In the discussion in chapter 5, I describe that it may be possible that endocytosis controls 
the signaling cascades. The relation of endocytosis and signaling is complicated, and it is 
possible that signaling can control endocytosis mechanism. For example, Src kinases function as 
downstream mediators of RTKs to increase the rate of de novo clathrin-coated pit formation by 
phosphorylating the clathrin heavy chain, leading to the assembly of the clathrin triskelion216. It 
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may be possible that kinase downstream of c-Kit signaling may trigger phosphorylation of 
clahtrin or caveolin, which increases the recruitment of clatrin/caveolin to the surface. It may be 
interesting to inhibit the kinase activities such as SRC kinase or PI3 kinase and examine the 
degree of phosphorylation of clathrin or caveolin. These experiments may give us an insight into 
the link between receptor signaling and induction of endocytosis.  
6.2.2 BONE MARROW TRANSPLANTATION 
Our study indicated that EPCs mobilize to peripheral blood after subcutaneous injection 
of tmSCFNDs treatment. To further investigate the mobilization and homing ability of EPCs, we 
will conduct GFP-expressing bone marrow transplantation. Eight to 10-week-old WT mice will 
be irradiated with 12.0 Gy of γ-irradiation in 2 divided doses, 2 hours apart, on the day of 
surgery. Bone marrow cells will be isolated from the femur and tibia of 8 to 10-week-old 
transgenic mice constitutively producing Green Fluorescent Proteins (GFPs). For bone marrow 
transplantation, wild-type irradiated mice will be injected with 0.2 ml PBS with or without 
2.0 × 105 BM mononuclear cells via tail veins at 2 hours after irradiation. Within 2–3 weeks, 
control animals should die while transplanted animals will survive and display 99% donor-
derived cells in the bone marrow. We will then conduct hind limb ischemia surgery on the BM 
transplanted mice then treat with our treatments. Peripheral blood and ischemic muscle tissues 
will be harvested after 1, 3, 4, 7 days of treatments to track the GFP positive BM cells. This will 
give us an additional confirmation of mobilization and homing ability of EPCs treated by 
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62 Lorena Lobos-González, L. A., Gonzalo Fernández, Carlos Sanhueza and Andrew F.G 
Quest. Caveolin-1 in Melanoma Progression. Advances in Malignant Melanoma, 187-214 
(2010). 
63 National Diabetes Statistics Report. (Centers for Disease Control and Prevention, Atlanta, 
GA, 2017). 
64 Barrientos, S., Brem, H., Stojadinovic, O. & Tomic-Canic, M. Clinical application of 
growth factors and cytokines in wound healing. Wound repair and regeneration : official 
 101 
publication of the Wound Healing Society [and] the European Tissue Repair Society 22, 
569-578, doi:10.1111/wrr.12205 (2014). 
65 Monteforte, A. J. et al. Glypican-1 nanoliposomes for potentiating growth factor activity 
in therapeutic angiogenesis. Biomaterials 94, 45-56, 
doi:10.1016/j.biomaterials.2016.03.048 (2016). 
66 Takematsu, E. et al. Genome wide analysis of gene expression changes in skin from 
patients with type 2 diabetes. PLoS One 15, e0225267, 
doi:10.1371/journal.pone.0225267 (2020). 
67 Hebbar, P. et al. Genetic risk variants for metabolic traits in Arab populations. Scientific 
reports 7, 40988-40988, doi:10.1038/srep40988 (2017). 
68 Bettahi, I. et al. Genome-wide transcriptional analysis of differentially expressed genes in 
diabetic, healing corneal epithelial cells: hyperglycemia-suppressed TGFβ3 expression 
contributes to the delay of epithelial wound healing in diabetic corneas. Diabetes 63, 715-
727, doi:10.2337/db13-1260 (2014). 
69 Yan, J. et al. Diabetes impairs wound healing by Dnmt1-dependent dysregulation of 
hematopoietic stem cells differentiation towards macrophages. Nature Communications 
9, 33, doi:10.1038/s41467-017-02425-z (2018). 
70 Chen, Y.-T., Liao, J.-W., Tsai, Y.-C. & Tsai, F.-J. Inhibition of DNA methyltransferase 1 
increases nuclear receptor subfamily 4 group A member 1 expression and decreases 
blood glucose in type 2 diabetes. Oncotarget 7, 39162-39170, 
doi:10.18632/oncotarget.10043 (2016). 
71 Thimmarayappa, J. et al. Inhibition of growth hormone receptor gene expression by 
saturated fatty acids: Role of Kruppel-like zinc finger factor, ZBP-89. Mol Endocrinol 
20, 2747-2760, doi:10.1210/me.2006-0128 (2006). 
72 Zhao, X. et al. Inhibition of CaMKIV relieves streptozotocin-induced diabetic 
neuropathic pain through regulation of HMGB1. Bmc Anesthesiol 16, doi:ARTN 27 
10.1186/s12871-016-0191-4 (2016). 
73 Zhao, X. et al. Inhibition of CaMKIV relieves streptozotocin-induced diabetic 
neuropathic pain through regulation of HMGB1. Bmc Anesthesiol 16, 27, 
doi:10.1186/s12871-016-0191-4 (2016). 
74 Iacobazzi, V. et al. Transcription of the mitochondrial citrate carrier gene: Identification 
of a silencer and its binding protein ZNF224. Biochem Bioph Res Co 386, 186-191, 
doi:10.1016/j.bbrc.2009.06.003 (2009). 
75 Kaplan, R. S., Oliveira, D. L. & Wilson, G. L. Streptozotocin-induced alterations in the 
levels of functional mitochondrial anion transport proteins. Arch Biochem Biophys 280, 
181-191 (1990). 
76 Gnoni, G. V. et al. Reduced activity and expression of mitochondrial citrate carrier in 
streptozotocin-induced diabetic rats. Endocrinology 151, 1551-1559, 
doi:10.1210/en.2009-1352 (2010). 
77 Meng, Z.-X., Wang, L., Xiao, Y. & Lin, J. D. The Baf60c/Deptor Pathway Links Skeletal 
Muscle Inflammation to Glucose Homeostasis in Obesity.  63, 1533-1545, 
doi:10.2337/db13-1061 %J Diabetes (2014). 
78 Meng, W. et al. A Genome-wide Association Study Provides Evidence of Sex-specific 
Involvement of Chr1p35.1 (ZSCAN20-TLR12P) and Chr8p23.1 (HMGB1P46) With 
Diabetic Neuropathic Pain. EBioMedicine 2, 1386-1393, 
doi:https://doi.org/10.1016/j.ebiom.2015.08.001 (2015). 
 102 
79 Suryavanshi, S. V., Jadhav, S. M. & McConnell, B. K. Polymorphisms/Mutations in A-
Kinase Anchoring Proteins (AKAPs): Role in the Cardiovascular System. Journal of 
cardiovascular development and disease 5, 7, doi:10.3390/jcdd5010007 (2018). 
80 Wang, X. et al. Histone deacetylase 4 selectively contributes to podocyte injury in 
diabetic nephropathy. Kidney International 86, 712-725, 
doi:https://doi.org/10.1038/ki.2014.111 (2014). 
81 Ung, C. et al. Whole exome sequencing identification of novel candidate genes in 
patients with proliferative diabetic retinopathy. Vision Research 139, 168-176, 
doi:https://doi.org/10.1016/j.visres.2017.03.007 (2017). 
82 Anderson, A. A. et al. Pancreatic islet expression profiling in diabetes-prone C57BLKS/J 
mice reveals transcriptional differences contributed by DBA loci, including Plagl1 and 
Nnt. PathoGenetics 2, 1-1, doi:10.1186/1755-8417-2-1 (2009). 
83 Berry, G. J., Frielle, C., Brucklacher, R. M., Salzberg, A. C. & Waldner, H. Identifying 
type 1 diabetes candidate genes by DNA microarray analysis of islet-specific CD4 + T 
cells. Genomics data 5, 184-188, doi:10.1016/j.gdata.2015.05.041 (2015). 
84 Baldari, S. et al. Hyperglycemia triggers HIPK2 protein degradation. Oncotarget 8, 1190-
1203, doi:10.18632/oncotarget.13595 (2016). 
85 Small, E. M., Vokes, S. A., Garriock, R. J., Li, D. & Krieg, P. A. Developmental 
expression of the Xenopus Nkx2-1 and Nkx2-4 genes. Mech Dev 96, 259-262 (2000). 
86 Lazzaro, D., Price, M., Defelice, M. & Dilauro, R. The Transcription Factor-Ttf-1 Is 
Expressed at the Onset of Thyroid and Lung Morphogenesis and in Restricted Regions of 
the Fetal Brain. Development 113, 1093-& (1991). 
87 Malt, E. A., Juhasz, K., Malt, U. F. & Naumann, T. A Role for the Transcription Factor 
Nk2 Homeobox 1 in Schizophrenia: Convergent Evidence from Animal and Human 
Studies. Frontiers in behavioral neuroscience 10, 59, doi:10.3389/fnbeh.2016.00059 
(2016). 
88 Coon, E. A., Ahlskog, J., Patterson, M. C., Niu, Z. & Milone, M. Expanding phenotypic 
spectrum of nkx2-1–related disorders—mitochondrial and immunologic dysfunction. 
JAMA Neurology 73, 237-238, doi:10.1001/jamaneurol.2015.2976 (2016). 
89 Sivitz, W. I. & Yorek, M. A. Mitochondrial dysfunction in diabetes: from molecular 
mechanisms to functional significance and therapeutic opportunities. Antioxidants & 
redox signaling 12, 537-577, doi:10.1089/ars.2009.2531 (2010). 
90 Magli, A. et al. Time-dependent Pax3-mediated chromatin remodeling and cooperation 
with Six4 and Tead2 specify the skeletal myogenic lineage in developing mesoderm. 
PLoS Biol 17, e3000153, doi:10.1371/journal.pbio.3000153 (2019). 
91 Chakroun, I. et al. Genome-wide association between Six4, MyoD, and the histone 
demethylase Utx during myogenesis. FASEB J 29, 4738-4755, doi:10.1096/fj.15-277053 
(2015). 
92 Konishi, Y., Ikeda, K., Iwakura, Y. & Kawakami, K. Six1 and Six4 promote survival of 
sensory neurons during early trigeminal gangliogenesis. Brain Res 1116, 93-102, 
doi:10.1016/j.brainres.2006.07.103 (2006). 
93 Said, G. Diabetic neuropathy--a review. Nat Clin Pract Neurol 3, 331-340, 
doi:10.1038/ncpneuro0504 (2007). 
94 D'Souza, D. M., Al-Sajee, D. & Hawke, T. J. Diabetic myopathy: impact of diabetes 
mellitus on skeletal muscle progenitor cells. Front Physiol 4, 379, 
doi:10.3389/fphys.2013.00379 (2013). 
 103 
95 Andersen, H., Schmitz, O. & Nielsen, S. Decreased isometric muscle strength after acute 
hyperglycaemia in Type 1 diabetic patients. Diabet Med 22, 1401-1407, 
doi:10.1111/j.1464-5491.2005.01649.x (2005). 
96 Xu, J. et al. Sequence analysis and structure prediction of ABHD16A and the roles of the 
ABHD family members in human disease. Open biology 8, 180017, 
doi:10.1098/rsob.180017 (2018). 
97 Hsieh, Y.-Y. et al. Human lymphocyte antigen B-associated transcript 2, 3, and 5 
polymorphisms and haplotypes are associated with susceptibility of Kawasaki disease 
and coronary artery aneurysm.  24, 262-268, doi:doi:10.1002/jcla.20409 (2010). 
98 Gaultier, A., Hollister, M., Reynolds, I., Hsieh, E.-h. & Gonias, S. L. LRP1 regulates 
remodeling of the extracellular matrix by fibroblasts. Matrix biology : journal of the 
International Society for Matrix Biology 29, 22-30, doi:10.1016/j.matbio.2009.08.003 
(2010). 
99 Nasarre, L. et al. Low density lipoprotein receptor–related protein 1 is upregulated in 
epicardial fat from type 2 diabetes mellitus patients and correlates with glucose and 
triglyceride plasma levels. Acta Diabetologica 51, 23-30, doi:10.1007/s00592-012-0436-
8 (2014). 
100 Park, S. Y. & Kim, I. S. Engulfment signals and the phagocytic machinery for apoptotic 
cell clearance. Exp Mol Med 49, e331, doi:10.1038/emm.2017.52 (2017). 
101 Kiss, R. S. et al. The lipoprotein receptor-related protein-1 (LRP) adapter protein GULP 
mediates trafficking of the LRP ligand prosaposin, leading to sphingolipid and free 
cholesterol accumulation in late endosomes and impaired efflux. J Biol Chem 281, 
12081-12092, doi:10.1074/jbc.M600621200 (2006). 
102 Wang, T., Baron, M. & Trump, D. An overview of Notch3 function in vascular smooth 
muscle cells. Prog Biophys Mol Biol 96, 499-509, doi:10.1016/j.pbiomolbio.2007.07.006 
(2008). 
103 Yuan, X. & Dong, Z. The Association Between the Genetic Variants of the NOTCH3 
Gene and Ischemic Stroke Risk. Medical science monitor : international medical journal 
of experimental and clinical research 22, 3910-3914, doi:10.12659/MSM.896297 (2016). 
104 Ozbayer, C. et al. The rs1043994 and rs3815188 genetic variations of the NOTCH3 gene 
and risk of type 2 diabetes mellitus. Biotechnol Biotec Eq 31, 563-567, 
doi:10.1080/13102818.2017.1294034 (2017). 
105 Roy, S. et al. Characterization of a preclinical model of chronic ischemic wound. Physiol 
Genomics 37, 211-224, doi:10.1152/physiolgenomics.90362.2008 (2009). 
106 Wong, G. H., Elwell, J. H., Oberley, L. W. & Goeddel, D. V. Manganous superoxide 
dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 
58, 923-931 (1989). 
107 Wang, Y., Branicky, R., Noe, A. & Hekimi, S. Superoxide dismutases: Dual roles in 
controlling ROS damage and regulating ROS signaling. J Cell Biol 217, 1915-1928, 
doi:10.1083/jcb.201708007 (2018). 
108 Bellot, G. L. et al. MnSOD is implicated in accelerated wound healing upon Negative 
Pressure Wound Therapy (NPWT): A case in point for MnSOD mimetics as adjuvants 
for wound management. Redox Biol 20, 307-320, doi:10.1016/j.redox.2018.10.014 
(2019). 
 104 
109 Fujiwara, T. et al. Extracellular superoxide dismutase deficiency impairs wound healing 
in advanced age by reducing neovascularization and fibroblast function. Exp Dermatol 
25, 206-211, doi:10.1111/exd.12909 (2016). 
110 Lawi, Z. K. K. Investigation of SOD2 Gene Polymorphism in the Patients with Type Two 
Diabetes Disease in Babylon Province. Journal of Global Pharma Thechnology 10, 70-75 
(2018). 
111 Tian, C., Fang, S., Du, X. & Jia, C. Association of the C47T polymorphism in SOD2 with 
diabetes mellitus and diabetic microvascular complications: a meta-analysis. 
Diabetologia 54, 803-811, doi:10.1007/s00125-010-2004-5 (2011). 
112 Chen, Y., Frost, S. & Byrne, J. A. Dropping in on the lipid droplet- tumor protein D52 
(TPD52) as a new regulator and resident protein. Adipocyte 5, 326-332, 
doi:10.1080/21623945.2016.1148835 (2016). 
113 Montgomery, M. K. & Turner, N. Mitochondrial dysfunction and insulin resistance: an 
update. Endocr Connect 4, R1-R15, doi:10.1530/EC-14-0092 (2015). 
114 Sethumadhavan, S. et al. Mitochondrial DNA variant for complex I reveals a role in 
diabetic cardiac remodeling. The Journal of biological chemistry 287, 22174-22182, 
doi:10.1074/jbc.M111.327866 (2012). 
115 Sinyov, V. V. et al. The heteroplasmy level of some mutations in gene MT-CYB among 
women with asymptomatic atherosclerosis. Russ J Genet+ 52, 847-852, 
doi:10.1134/S1022795416080123 (2016). 
116 Van Vranken, J. G. et al. SDHAF4 promotes mitochondrial succinate dehydrogenase 
activity and prevents neurodegeneration. Cell metabolism 20, 241-252, 
doi:10.1016/j.cmet.2014.05.012 (2014). 
117 Nilsson, E. et al. Altered DNA Methylation and Differential Expression of Genes 
Influencing Metabolism and Inflammation in Adipose Tissue From Subjects With Type 2 
Diabetes.  63, 2962-2976, doi:10.2337/db13-1459 %J Diabetes (2014). 
118 Xie, X. et al. Proteomics analyses of subcutaneous adipocytes reveal novel abnormalities 
in human insulin resistance. Obesity (Silver Spring, Md.) 24, 1506-1514, 
doi:10.1002/oby.21528 (2016). 
119 Rovira-Llopis, S. et al. Mitochondrial dynamics in type 2 diabetes: Pathophysiological 
implications. Redox Biology 11, 637-645, doi:https://doi.org/10.1016/j.redox.2017.01.013 
(2017). 
120 Kulkarni, S. S. et al. Mfn1 Deficiency in the Liver Protects Against Diet-Induced Insulin 
Resistance and Enhances the Hypoglycemic Effect of Metformin.  65, 3552-3560, 
doi:10.2337/db15-1725 %J Diabetes (2016). 
121 Popov, K. M.     (National Institutes of Health, University of Alabama Birmingham, 
2010). 
122 Pink, R. C. et al. Pseudogenes: pseudo-functional or key regulators in health and disease? 
RNA 17, 792-798, doi:10.1261/rna.2658311 (2011). 
123 Ansseau, E. et al. Homologous Transcription Factors DUX4 and DUX4c Associate with 
Cytoplasmic Proteins during Muscle Differentiation. PloS one 11, e0146893-e0146893, 
doi:10.1371/journal.pone.0146893 (2016). 
124 Bosnakovski, D., Daughters, R. S., Xu, Z., Slack, J. M. W. & Kyba, M. Biphasic 
myopathic phenotype of mouse DUX, an ORF within conserved FSHD-related repeats. 
PloS one 4, e7003-e7003, doi:10.1371/journal.pone.0007003 (2009). 
 105 
125 Bosnakovski, D. et al. Low level DUX4 expression disrupts myogenesis through 
deregulation of myogenic gene expression. Sci Rep 8, 16957, doi:10.1038/s41598-018-
35150-8 (2018). 
126 Vanderplanck, C. et al. Overexpression of the double homeodomain protein DUX4c 
interferes with myofibrillogenesis and induces clustering of myonuclei. Skelet Muscle 8, 
2, doi:10.1186/s13395-017-0148-4 (2018). 
127 Ansseau, E. et al. Homologous Transcription Factors DUX4 and DUX4c Associate with 
Cytoplasmic Proteins during Muscle Differentiation. PLoS One 11, e0146893, 
doi:10.1371/journal.pone.0146893 (2016). 
128 Liu, Y. et al. A genetic variant in long non-coding RNA HULC contributes to risk of 
HBV-related hepatocellular carcinoma in a Chinese population. PloS one 7, e35145-
e35145, doi:10.1371/journal.pone.0035145 (2012). 
129 Batista, P. J. & Chang, H. Y. Long noncoding RNAs: cellular address codes in 
development and disease. Cell 152, 1298-1307, doi:10.1016/j.cell.2013.02.012 (2013). 
130 Schonrock, N., Harvey, R. P. & Mattick, J. S. Long Noncoding RNAs in Cardiac 
Development and Pathophysiology.  111, 1349-1362, 
doi:doi:10.1161/CIRCRESAHA.112.268953 (2012). 
131 Tan, L., Yu, J.-T., Hu, N. & Tan, L. Non-coding RNAs in Alzheimer's Disease. 
Molecular Neurobiology 47, 382-393, doi:10.1007/s12035-012-8359-5 (2013). 
132 Faghihi, M. A. et al. Expression of a noncoding RNA is elevated in Alzheimer's disease 
and drives rapid feed-forward regulation of beta-secretase. Nature medicine 14, 723-730, 
doi:10.1038/nm1784 (2008). 
133 Wang, T.-H. et al. Long noncoding RNA CPS1-IT1 suppresses the metastasis of 
hepatocellular carcinoma by regulating HIF-1α activity and inhibiting epithelial-
mesenchymal transition. Oncotarget 7, 43588-43603, doi:10.18632/oncotarget.9635 
(2016). 
134 Vial, I. N. et al. HIF-1α dysfunction in diabetes AU - Thangarajah, Hariharan. Cell Cycle 
9, 75-79, doi:10.4161/cc.9.1.10371 (2010). 
135 Shi, C. & Wang, M. LINC01118 Modulates Paclitaxel Resistance of Epithelial Ovarian 
Cancer by Regulating miR-134/ABCC1. Medical science monitor : international medical 
journal of experimental and clinical research 24, 8831-8839, doi:10.12659/MSM.910932 
(2018). 
136 Shi, X., Guo, X., Li, X., Wang, M. & Qin, R. Loss of Linc01060 induces pancreatic 
cancer progression through vinculin-mediated focal adhesion turnover. Cancer Lett 433, 
76-85, doi:10.1016/j.canlet.2018.06.015 (2018). 
137 Ling, C., Groop, L., Guerra, S. D. & Lupi, R. Calpain-10 expression is elevated in 
pancreatic islets from patients with type 2 diabetes. PloS one 4, e6558-e6558, 
doi:10.1371/journal.pone.0006558 (2009). 
138 Wight, M. & Werner, A. The functions of natural antisense transcripts. Essays in 
biochemistry 54, 91-101, doi:10.1042/bse0540091 (2013). 
139 Gu, Y. et al. Differential gene expression profiling of the sciatic nerve in type 1 and type 
2 diabetic mice. Biomedical reports 9, 291-304, doi:10.3892/br.2018.1135 (2018). 
140 Blackburn, K., Bustamante-Marin, X., Yin, W., Goshe, M. B. & Ostrowski, L. E. 
Quantitative Proteomic Analysis of Human Airway Cilia Identifies Previously 
Uncharacterized Proteins of High Abundance. J Proteome Res 16, 1579-1592, 
doi:10.1021/acs.jproteome.6b00972 (2017). 
 106 
141 Gupta, M. et al. TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major 
depressive disorder: pharmacometabolomics-informed pharmacogenomics. Mol 
Psychiatry 21, 1717-1725, doi:10.1038/mp.2016.6 (2016). 
142 Mangelsdorf, D. J. et al. The nuclear receptor superfamily: the second decade. Cell 83, 
835-839 (1995). 
143 Corton, J. C., Anderson, S. P. & Stauber, A. Central Role of Peroxisome Proliferator–
Activated Receptors in the Actions of Peroxisome Proliferators.  40, 491-518, 
doi:10.1146/annurev.pharmtox.40.1.491 (2000). 
144 Guan, F. et al. Two-stage association study to identify the genetic susceptibility of a 
novel common variant of rs2075290 in ZPR1 to type 2 diabetes. Scientific reports 6, 
29586-29586, doi:10.1038/srep29586 (2016). 
145 Yoshihito Nogusa, N. Y., Naoki Sumiyoshi, Keiko Takeda, Norihisa Kato Expression of 
zinc finger protein ZPR1 mRNA in brain is up-regulated in mice fed a high-fat diet. 
International journal of molecular medicine 17(3), 491-496 (2006). 
146 Hansen, J. S. et al. Type 2 diabetes alters metabolic and transcriptional signatures of 
glucose and amino acid metabolism during exercise and recovery. Diabetologia 58, 
1845-1854, doi:10.1007/s00125-015-3584-x (2015). 
147 Berry, G. J., Frielle, C., Brucklacher, R. M., Salzberg, A. C. & Waldner, H. Identifying 
type 1 diabetes candidate genes by DNA microarray analysis of islet-specific CD4 + T 
cells. Genom Data 5, 184-188, doi:10.1016/j.gdata.2015.05.041 (2015). 
148 Bettahi, I. et al. Genome-Wide Transcriptional Analysis of Differentially Expressed 
Genes in Diabetic, Healing Corneal Epithelial Cells: Hyperglycemia-Suppressed TGFβ3 
Expression Contributes to the Delay of Epithelial Wound Healing in Diabetic Corneas.  
63, 715-727, doi:10.2337/db13-1260 %J Diabetes (2014). 
149 Hien, T. T. et al. Elevated Glucose Levels Promote Contractile and Cytoskeletal Gene 
Expression in Vascular Smooth Muscle via Rho/Protein Kinase C and Actin 
Polymerization. The Journal of biological chemistry 291, 3552-3568, 
doi:10.1074/jbc.M115.654384 (2016). 
150 Cai, Y. & Zeng, C. GW29-e1533 MYO1F exacerbates atherogenesis and can be as a 
novel candidate biomarker for patients with obstructive coronary artery disease or 
advanced atherosclerosis.  72, C74, doi:10.1016/j.jacc.2018.08.419 %J Journal of the 
American College of Cardiology (2018). 
151 Karthik, D., Ilavenil, S., Kaleeswaran, B., Sunil, S. & Ravikumar, S. Proteomic Analysis 
of Plasma Proteins in Diabetic Rats by 2D Electrophoresis and MALDI-TOF-MS. 
Applied Biochemistry and Biotechnology 166, 1507-1519, doi:10.1007/s12010-012-9544-
8 (2012). 
152 Weijers, R. N. Lipid composition of cell membranes and its relevance in type 2 diabetes 
mellitus. Curr Diabetes Rev 8, 390-400 (2012). 
153 Gottfried, I., Ehrlich, M. & Ashery, U. The Sla2p/HIP1/HIP1R family: similar structure, 
similar function in endocytosis?  38, 187-191, doi:10.1042/BST0380187 %J Biochemical 
Society Transactions (2010). 
154 Berchtold, L. A. et al. Huntingtin-interacting protein 14 is a type 1 diabetes candidate 
protein regulating insulin secretion and β-cell apoptosis.  108, E681-E688, 
doi:10.1073/pnas.1104384108 %J Proceedings of the National Academy of Sciences 
(2011). 
155 in Type 2 Diabetes Mellitus_Pancreas_GSE2470    (Harmonizome). 
 107 
156 Rodríguez-Fraticelli, A. E. et al. Developmental regulation of apical endocytosis controls 
epithelial patterning in vertebrate tubular organs. Nature cell biology 17, 241-250, 
doi:10.1038/ncb3106 (2015). 
157 Le Guelte, A. & Macara, I. G. Plasmolipin--a new player in endocytosis and epithelial 
development. The EMBO journal 34, 1147-1148, doi:10.15252/embj.201591448 (2015). 
158 Shu, B. & Yang, R. H. Notch1 Signaling Regulates Wound Healing via Changing the 
Characteristics of Epidermal Stem Cells. Journal of Stem Cell Research & Therapy 2016, 
doi:10.4172/2157-7633.1000348 (2016). 
159 Khalfaoui, T. et al. Laminin receptor 37/67LR regulates adhesion and proliferation of 
normal human intestinal epithelial cells. PLoS One 8, e74337, 
doi:10.1371/journal.pone.0074337 (2013). 
160 Miragliotta, V., Lussier, J. G. & Theoret, C. L. Laminin receptor 1 is differentially 
expressed in thoracic and limb wounds in the horse. Vet Dermatol 20, 27-34, 
doi:10.1111/j.1365-3164.2008.00718.x (2009). 
161 Longmate, W. M. et al. Suppression of integrin alpha3beta1 by alpha9beta1 in the 
epidermis controls the paracrine resolution of wound angiogenesis. J Cell Biol 216, 1473-
1488, doi:10.1083/jcb.201510042 (2017). 
162 Margadant, C. et al. Integrin alpha3beta1 inhibits directional migration and wound re-
epithelialization in the skin. J Cell Sci 122, 278-288, doi:10.1242/jcs.029108 (2009). 
163 Reynolds, L. E. et al. alpha3beta1 integrin-controlled Smad7 regulates reepithelialization 
during wound healing in mice. J Clin Invest 118, 965-974, doi:10.1172/JCI33538 (2008). 
164 Weis, S. M. & Cheresh, D. A. alphaV integrins in angiogenesis and cancer. Cold Spring 
Harb Perspect Med 1, a006478, doi:10.1101/cshperspect.a006478 (2011). 
165 Longmate, W. M. & Dipersio, C. M. Integrin Regulation of Epidermal Functions in 
Wounds. Adv Wound Care (New Rochelle) 3, 229-246, doi:10.1089/wound.2013.0516 
(2014). 
166 Gragnano, F. et al. The Role of von Willebrand Factor in Vascular Inflammation: From 
Pathogenesis to Targeted Therapy. Mediators Inflamm 2017, 5620314, 
doi:10.1155/2017/5620314 (2017). 
167 Frankel, D. S. et al. Von Willebrand factor, type 2 diabetes mellitus, and risk of 
cardiovascular disease: the framingham offspring study. Circulation 118, 2533-2539, 
doi:10.1161/CIRCULATIONAHA.108.792986 (2008). 
168 Seligman, B. G., Biolo, A., Polanczyk, C. A., Gross, J. L. & Clausell, N. Increased 
plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes 
and dyslipidemia.  23, 1395-1400, doi:10.2337/diacare.23.9.1395 %J Diabetes Care 
(2000). 
169 Mannucci, P. M. von Willebrand Factor.  18, 1359-1362, 
doi:doi:10.1161/01.ATV.18.9.1359 (1998). 
170 Tajhya, R. B. et al. Functional KCa1.1 channels are crucial for regulating the 
proliferation, migration and differentiation of human primary skeletal myoblasts. Cell 
Death Dis 7, e2426, doi:10.1038/cddis.2016.324 (2016). 
171 Tanner, M. R. et al. KCa1.1 and Kv1.3 channels regulate the interactions between 
fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis. Arthritis Res 
Ther 21, 6, doi:10.1186/s13075-018-1783-9 (2019). 
172 Tanner, M. R., Pennington, M. W., Laragione, T., Gulko, P. S. & Beeton, C. KCa1.1 
channels regulate beta1-integrin function and cell adhesion in rheumatoid arthritis 
 108 
fibroblast-like synoviocytes. FASEB J 31, 3309-3320, doi:10.1096/fj.201601097R 
(2017). 
173 Takagi, N. et al. IL-17A promotes neutrophilic inflammation and disturbs acute wound 
healing in skin. Exp Dermatol 26, 137-144, doi:10.1111/exd.13115 (2017). 
174 Lambert, S., Swindell, W. R., Tsoi, L. C., Stoll, S. W. & Elder, J. T. Dual Role of Act1 in 
Keratinocyte Differentiation and Host Defense: TRAF3IP2 Silencing Alters Keratinocyte 
Differentiation and Inhibits IL-17 Responses. J Invest Dermatol 137, 1501-1511, 
doi:10.1016/j.jid.2016.12.032 (2017). 
175 Carrier, Y. et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and 
in vivo: implications in psoriasis pathogenesis. J Invest Dermatol 131, 2428-2437, 
doi:10.1038/jid.2011.234 (2011). 
176 Jiang, Z. et al. IL-36gamma Induced by the TLR3-SLUG-VDR Axis Promotes Wound 
Healing via REG3A. J Invest Dermatol 137, 2620-2629, doi:10.1016/j.jid.2017.07.820 
(2017). 
177 Wu, C., Chen, X., Shu, J. & Lee, C. T. Whole-genome expression analyses of type 2 
diabetes in human skin reveal altered immune function and burden of infection. 
Oncotarget 8, 34601-34609, doi:10.18632/oncotarget.16118 (2017). 
178 Ramirez, H. A. et al. Comparative Genomic, MicroRNA, and Tissue Analyses Reveal 
Subtle Differences between Non-Diabetic and Diabetic Foot Skin. PLoS One 10, 
e0137133, doi:10.1371/journal.pone.0137133 (2015). 
179 Theocharidis, G., Bhasin, S. S., Kounas, K., Bhasin, M. K. & Veves, A. Single Cell 
RNA-Seq Analyses of Healthy Lower Extremity Skin and Diabetic Foot Ulcers Uncover 
Distinct Immune Landscape of Diabetic Wound Healing. Diabetes 67, 647-P, 
doi:10.2337/db18-647-P (2018). 
180 Das, S. et al. Syndesome Therapeutics for Enhancing Diabetic Wound Healing. Adv 
Healthc Mater 5, 2248-2260, doi:10.1002/adhm.201600285 (2016). 
181 Jang, E., Albadawi, H., Watkins, M. T., Edelman, E. R. & Baker, A. B. Syndecan-4 
proteoliposomes enhance fibroblast growth factor-2 (FGF-2)-induced proliferation, 
migration, and neovascularization of ischemic muscle. Proc Natl Acad Sci U S A 109, 
1679-1684, doi:10.1073/pnas.1117885109 (2012). 
182 Schiekofer, S., Galasso, G., Sato, K., Kraus, B. J. & Walsh, K. Impaired revascularization 
in a mouse model of type 2 diabetes is associated with dysregulation of a complex 
angiogenic-regulatory network. Arterioscler Thromb Vasc Biol 25, 1603-1609, 
doi:10.1161/01.ATV.0000171994.89106.ca (2005). 
183 Takematsu, E. et al. Genome wide analysis of gene expression changes in skin from 
patients with type 2 diabetes. PLoS One 15, e0225267, 
doi:10.1371/journal.pone.0225267 (2020). 
184 Das, S., Majid, M. & Baker, A. B. Syndecan-4 enhances PDGF-BB activity in diabetic 
wound healing. Acta Biomater 42, 56-65, doi:10.1016/j.actbio.2016.07.001 (2016). 
185 Das, S. et al. Syndecan-4 Enhances Therapeutic Angiogenesis after Hind Limb Ischemia 
in Mice with Type 2 Diabetes. Adv Healthc Mater 5, 1008-1013, 
doi:10.1002/adhm.201500993 (2016). 
186 Das, S., Singh, G. & Baker, A. B. Overcoming disease-induced growth factor resistance 
in therapeutic angiogenesis using recombinant co-receptors delivered by a liposomal 
system. Biomaterials 35, 196-205, doi:10.1016/j.biomaterials.2013.09.105 (2014). 
 109 
187 Rodrigues, M. et al. Progenitor cell dysfunctions underlie some diabetic complications. 
Am J Pathol 185, 2607-2618, doi:10.1016/j.ajpath.2015.05.003 (2015). 
188 Kang, L. et al. Decreased mobilization of endothelial progenitor cells contributes to 
impaired neovascularization in diabetes. Clinical and Experimental Pharmacology and 
Physiology 36, e47-e56, doi:10.1111/j.1440-1681.2009.05219.x (2009). 
189 Das, S. et al. Syndesome Therapeutics for Enhancing Diabetic Wound Healing. Adv 
Healthc Mater 5, 2248-2260, doi:10.1002/adhm.201600285 (2016). 
190 Taylor, A. M., Galli, S. J. & Coleman, J. W. Stem-cell factor, the kit ligand, induces 
direct degranulation of rat peritoneal mast cells in vitro and in vivo: dependence of the in 
vitro effect on period of culture and comparisons of stem-cell factor with other mast cell-
activating agents. Immunology 86, 427-433 (1995). 
191 Da Silva, C. A., Reber, L. & Frossard, N. Stem cell factor expression, mast cells and 
inflammation in asthma. Fundamental & Clinical Pharmacology 20, 21-39, 
doi:10.1111/j.1472-8206.2005.00390.x (2006). 
192 Friedrich Erik, B., Walenta, K., Scharlau, J., Nickenig, G. & Werner, N. 
CD34−/CD133+/VEGFR-2+ Endothelial Progenitor Cell Subpopulation With Potent 
Vasoregenerative Capacities. Circulation Research 98, e20-e25, 
doi:10.1161/01.RES.0000205765.28940.93 (2006). 
193 Mihail Hristov, A. Z., Elisa A Liehn, Christian Weber. Regulation of endothelial 
progenitor cell homing after arterial injury. Thrombosis and haemostasis 98 2, 274-277 
(2007). 
194 Li, X. et al. Administration of signalling molecules dictates stem cell homing for in situ 
regeneration. J Cell Mol Med 21, 3162-3177, doi:10.1111/jcmm.13286 (2017). 
195 Fitridge, R., Pena, G. & Mills, J. L. The patient presenting with chronic limb-threatening 
ischaemia. Does diabetes influence presentation, limb outcomes and survival? Diabetes 
Metab Res Rev, e3242, doi:10.1002/dmrr.3242 (2019). 
196 Takahara, M. et al. Diabetes mellitus and other cardiovascular risk factors in lower-
extremity peripheral artery disease versus coronary artery disease: an analysis of 
1,121,359 cases from the nationwide databases. Cardiovasc Diabetol 18, 155, 
doi:10.1186/s12933-019-0955-5 (2019). 
197 Susumu Yamazaki, N. N., Asuka Honjo, Mutsuko Hara, Keiko Maeda, Chiharu 
Nishiyama, Jiro Kitaura, Yoshikazu Ohtsuka, Ko Okumura, Hideoki Ogawa and Toshiaki 
Shimizu. The Transcription Factor Ehf Is Involved in TGF-β–Induced Suppression of 
FcεRI and c-Kit Expression and FcεRI-Mediated Activation in Mast Cells. The journal of 
immunology 195, 3427-3435, doi:https://doi.org/10.4049/jimmunol.1402856 (2015). 
198 Yang, J. et al. CD34+ cells represent highly functional endothelial progenitor cells in 
murine bone marrow. PLoS One 6, e20219-e20219, doi:10.1371/journal.pone.0020219 
(2011). 
199 Ekmekcioglu, S., Kurzrock, R. & Grimm, E. A. in The Molecular Basis of Cancer 
(Fourth Edition)   (eds John Mendelsohn et al.)  789-808.e784 (Content Repository 
Only!, 2015). 
200 Cruse, G. et al. The CD20 homologue MS4A4 directs trafficking of KIT toward clathrin-
independent endocytosis pathways and thus regulates receptor signaling and recycling. 
Mol Biol Cell 26, 1711-1727, doi:10.1091/mbc.E14-07-1221 (2015). 
201 Goh, L. K. & Sorkin, A. Endocytosis of receptor tyrosine kinases. Cold Spring Harb 
Perspect Biol 5, a017459-a017459, doi:10.1101/cshperspect.a017459 (2013). 
 110 
202 Cruse, G. et al. The CD20 homologue MS4A4 directs trafficking of KIT toward clathrin-
independent endocytosis pathways and thus regulates receptor signaling and recycling. 
Mol Biol Cell 26, 1711-1727, doi:10.1091/mbc.E14-07-1221 (2015). 
203 Lartigue, J. d. The SCF/KIT Pathway's Roles: Interest in Therapeutic Targets Is 
Growing, <https://www.onclive.com/publications/oncology-live/2011/august-2011/the-
scfkit-pathways-roles-interest-in-therapeutic-targets-is-growing> (2011). 
204 Morales, J. K., Falanga, Y. T., Depcrynski, A., Fernando, J. & Ryan, J. J. Mast cell 
homeostasis and the JAK–STAT pathway. Genes & Immunity 11, 599-608, 
doi:10.1038/gene.2010.35 (2010). 
205 Bai, X.-L. et al. Cavin-1 regulates caveolae-mediated LDL transcytosis: crosstalk in an 
AMPK/eNOS/ NF-&#x03BA;B/Sp1 loop.  8 (2017). 
206 Gerbod-Giannone, M.-C. et al. Involvement of caveolin-1 and CD36 in native LDL 
endocytosis by endothelial cells. Biochimica et Biophysica Acta (BBA) - General Subjects 
1863, 830-838, doi:https://doi.org/10.1016/j.bbagen.2019.01.005 (2019). 
207 Ramírez Cristina, M. et al. Caveolin-1 Regulates Atherogenesis by Attenuating Low-
Density Lipoprotein Transcytosis and Vascular Inflammation Independently of 
Endothelial Nitric Oxide Synthase Activation. Circulation 140, 225-239, 
doi:10.1161/CIRCULATIONAHA.118.038571 (2019). 
208 Rejman, J., Oberle, V., Zuhorn, I. S. & Hoekstra, D. Size-dependent internalization of 
particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 
377, 159-169, doi:10.1042/BJ20031253 (2004). 
209 Henley, J. R., Krueger, E. W., Oswald, B. J. & McNiven, M. A. Dynamin-mediated 
internalization of caveolae. J Cell Biol 141, 85-99, doi:10.1083/jcb.141.1.85 (1998). 
210 Tran, D., Carpentier, J. L., Sawano, F., Gorden, P. & Orci, L. Ligands internalized 
through coated or noncoated invaginations follow a common intracellular pathway. Proc 
Natl Acad Sci U S A 84, 7957-7961, doi:10.1073/pnas.84.22.7957 (1987). 
211 Chen, Y.-G. Endocytic regulation of TGF-β signaling. Cell Research 19, 58-70, 
doi:10.1038/cr.2008.315 (2009). 
212 Kazi, J. U., Agarwal, S., Sun, J., Bracco, E. & Rönnstrand, L. Src-like-adaptor protein 
(SLAP) differentially regulates normal and oncogenic c-Kit signaling. Journal of Cell 
Science 127, 653, doi:10.1242/jcs.140590 (2014). 
213 Couet, J., Sargiacomo, M. & Lisanti, M. P. Interaction of a Receptor Tyrosine Kinase, 
EGF-R, with Caveolins: CAVEOLIN BINDING NEGATIVELY REGULATES 
TYROSINE AND SERINE/THREONINE KINASE ACTIVITIES.  272, 30429-30438, 
doi:10.1074/jbc.272.48.30429 (1997). 
214 Reid, D. J. et al. Engineering Nanodisc Scaffold Proteins for Native Mass Spectrometry. 
Anal Chem 89, 11189-11192, doi:10.1021/acs.analchem.7b03569 (2017). 
215 Grinkova, Y. V., Denisov, I. G. & Sligar, S. G. Engineering extended membrane scaffold 
proteins for self-assembly of soluble nanoscale lipid bilayers. Protein Eng Des Sel 23, 
843-848, doi:10.1093/protein/gzq060 (2010). 
216 Sorkin, A. & von Zastrow, M. Endocytosis and signalling: intertwining molecular 
networks. Nat Rev Mol Cell Biol 10, 609-622, doi:10.1038/nrm2748 (2009). 
 
 
